10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to            

Commission File Number: 001-35568 (Healthcare Trust of America, Inc.)

Commission File Number: 333-190916 (Healthcare Trust of America Holdings, LP)

_________________________ 

HEALTHCARE TRUST OF AMERICA, INC.

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

(Exact name of registrant as specified in its charter)

Maryland (Healthcare Trust of America, Inc.)	20-4738467
Delaware (Healthcare Trust of America Holdings, LP)	20-4738347
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

16435 N. Scottsdale Road, Suite 320

Scottsdale, Arizona 85254

(Address of principal executive offices)

(480) 998-3478

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    

Healthcare Trust of America, Inc.	x Yes	¨ No
Healthcare Trust of America Holdings, LP	x Yes	¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    

Healthcare Trust of America, Inc.	x Yes	¨ No
Healthcare Trust of America Holdings, LP	x Yes	¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Healthcare Trust of America, Inc.	Large-accelerated filer x	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company ¨
			(Do not check if a smaller reporting company)
Healthcare Trust of America Holdings, LP	Large-accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer x	Smaller reporting company ¨
			(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   

Healthcare Trust of America, Inc.	¨ Yes	x No
Healthcare Trust of America Holdings, LP	¨ Yes	x No

As of October 27, 2014, there were 238,946,821 shares of Class A common stock of Healthcare Trust of America, Inc. outstanding.

Explanatory Note

This report combines the Quarterly Reports on Form 10-Q for the quarter ended September 30, 2014 of Healthcare Trust of America, Inc. (“HTA”), a Maryland corporation, and Healthcare Trust of America Holdings, LP (“HTALP”), a Delaware limited partnership. Unless otherwise indicated or unless the context requires otherwise, all references in this Quarterly Report to “we,” “us,” “our,” “the Company” or “our Company” refer to HTA and HTALP, collectively.

HTA operates as a real estate investment trust (“REIT”) and is the general partner of HTALP. As of September 30, 2014, HTA owned a 99.0% partnership interest in HTALP, and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the long term incentive plan (“LTIP”) units) in HTALP. As the sole general partner of HTALP, HTA has the full, exclusive and complete responsibility for HTALP’s day-to-day management and control, including its compliance with the Securities and Exchange Commission (“SEC”) filing requirements.

We believe it is important to understand the few differences between HTA and HTALP in the context of how we operate as an integrated consolidated company. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP. As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP, issuing public equity from time to time and guaranteeing certain debts of HTALP. HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity. Except for net proceeds from public equity issuances by HTA, which are generally contributed to HTALP in exchange for partnership units, HTALP generates the capital required for the business through its operations, and by direct or indirect incurrence of indebtedness or through the issuance of its partnership units.

Redeemable noncontrolling interests of limited partners, stockholders’ equity and partners’ capital are the primary areas of difference between the condensed consolidated financial statements of HTA and HTALP. Limited partnership units in HTALP are accounted for as partners’ capital in HTALP’s condensed consolidated balance sheets and as noncontrolling interest reflected within equity or redeemable noncontrolling interest of limited partners reflected outside of equity in HTA’s condensed consolidated balance sheets. The differences between HTA’s stockholders’ equity and HTALP’s partners’ capital are due to the differences in the equity issued by HTA and HTALP, respectively.

The Company believes combining the Quarterly Reports on Form 10-Q of HTA and HTALP, including the notes to the condensed consolidated financial statements, into this single Quarterly Report results in the following benefits:

• enhances stockholders’ understanding of HTA and HTALP by enabling stockholders to view the business as a whole in the same manner that management views and operates the business;

• eliminates duplicative disclosure and provides a more streamlined and readable presentation since a substantial portion of the disclosure in this Quarterly Report applies to both HTA and HTALP; and

• creates time and cost efficiencies through the preparation of a single combined Quarterly Report instead of two separate Quarterly Reports.

In order to highlight the material differences between HTA and HTALP, this Quarterly Report includes sections that separately present and discuss areas that are materially different between HTA and HTALP, including:

• the condensed consolidated financial statements;

• certain accompanying notes to the condensed consolidated financial statements, including Note 8 - Debt, Note 11 - Stockholders’ Equity and Partners’ Capital, Note 13 - Per Share Data of HTA, and Note 14 - Per Unit Data of HTALP;

• the Funds From Operations (“FFO”) and Normalized FFO in Part I, Item 2 of this Quarterly Report;

• the controls and procedures in Part I, Item 4 of this Quarterly Report; and

• the certifications of the Chief Executive Officer and the Chief Financial Officer included as Exhibits 31 and 32 to this Quarterly Report.

In the sections of this Quarterly Report that combine disclosure for HTA and HTALP, this Quarterly Report refers to actions or holdings as being actions or holdings of the Company. Although HTALP (directly or indirectly through one of its subsidiaries) is generally the entity that enters into contracts, holds assets and issues or incurs debt, management believes this presentation is appropriate for the reasons set forth above and because the business of the Company is a single integrated enterprise operated through HTALP.

2

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

TABLE OF CONTENTS

		Page
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	4
Healthcare Trust of America, Inc.
	Condensed Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013	4
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2014 and 2013	5
	Condensed Consolidated Statements of Equity for the Nine Months Ended September 30, 2014 and 2013	6
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 and 2013	7
Healthcare Trust of America Holdings, LP
	Condensed Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013	8
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2014 and 2013	9
	Condensed Consolidated Statements of Changes in Partners’ Capital for the Nine Months Ended September 30, 2014 and 2013	10
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 and 2013	11
Notes for Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP
	Notes to Unaudited Condensed Consolidated Financial Statements	12
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36
Item 4.	Controls and Procedures	37
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	38
Item 1A.	Risk Factors	38
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	38
Item 6.	Exhibits	38
Signatures		39

3

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

	September 30, 2014			December 31, 2013
ASSETS
Real estate investments:
Land	$	272,922		$	203,001
Building and improvements	2,554,006			2,358,071
Lease intangibles	413,403			411,857
	3,240,331			2,972,929
Accumulated depreciation and amortization	(518,647		)	(445,938		)
Real estate investments, net (see Note 2)	2,721,684			2,526,991
Assets held for sale, net	22,930			—
Real estate notes receivable	8,520			28,520
Cash and cash equivalents	18,415			18,081
Restricted cash and escrow deposits	31,329			18,114
Receivables and other assets, net	141,561			110,285
Other intangibles, net	42,362			50,343
Total assets	$	2,986,801		$	2,752,334
LIABILITIES AND EQUITY
Liabilities:
Debt	$	1,497,136		$	1,214,241
Accounts payable and accrued liabilities	98,163			82,893
Derivative financial instruments - interest rate swaps	4,127			5,053
Security deposits, prepaid rent and other liabilities	31,935			35,339
Intangible liabilities, net	11,520			11,797
Total liabilities	1,642,881			1,349,323
Commitments and contingencies
Redeemable noncontrolling interest of limited partners	3,258			3,262
Equity:
Preferred stock, $0.01 par value; 200,000,000 shares authorized; none issued and outstanding	—			—
Class A common stock, $0.01 par value; 1,000,000,000 shares authorized; 238,944,761 and 236,880,614 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	2,389			2,369
Additional paid-in capital	2,147,688			2,126,897
Cumulative dividends in excess of earnings	(820,978		)	(742,060		)
Total stockholders’ equity	1,329,099			1,387,206
Noncontrolling interest	11,563			12,543
Total equity	1,340,662			1,399,749
Total liabilities and equity	$	2,986,801		$	2,752,334

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Revenues:
Rental income	$	95,277		$	82,349		$	274,675		$	235,595
Interest income from real estate notes receivable	257			635			1,834			1,874
Total revenues	95,534			82,984			276,509			237,469
Expenses:
Rental	28,526			25,837			85,179			72,435
General and administrative	5,935			5,980			18,137			18,645
Acquisition-related	2,802			1,403			8,647			3,086
Depreciation and amortization	35,802			29,581			104,346			87,725
Listing	—			—			—			4,405
Total expenses	73,065			62,801			216,309			186,296
Income before other income (expense)	22,469			20,183			60,200			51,173
Other income (expense):
Interest expense:
Interest related to derivative financial instruments	(1,433		)	(1,087		)	(4,148		)	(3,448		)
Net gain (loss) on change in the fair value of derivative financial instruments	2,564			(1,955		)	(857		)	8,573
Total interest related to derivative financial instruments, including net change in the fair value of derivative financial instruments	1,131			(3,042		)	(5,005		)	5,125
Interest related to debt	(14,119		)	(12,146		)	(37,802		)	(35,704		)
Gain on sales of real estate	11,766			—			11,766			—
Loss on extinguishment of debt, net	(5,028		)	—			(4,663		)	—
Other income	1			10			41			28
Net income	$	16,220		$	5,005		$	24,537		$	20,622
Net income attributable to noncontrolling interests (1)	(188		)	(182		)	(358		)	(423		)
Net income attributable to common stockholders	$	16,032		$	4,823		$	24,179		$	20,199
Earnings per common share - basic
Net income attributable to common stockholders	$	0.07		$	0.02		$	0.10		$	0.09
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.07		$	0.02		$	0.10		$	0.09
Weighted average number of common shares outstanding:
Basic	238,968			232,514			238,099			225,132
Diluted	241,432			235,023			240,608			226,771
Dividends declared per common share	$	0.15		$	0.14		$	0.43		$	0.43
(1) Includes amounts attributable to redeemable noncontrolling interests.

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(In thousands)

(Unaudited)

	Common Stock Issued				Par Value			Additional Paid-In Capital			Cumulative Dividends in Excess of Earnings			Total Stockholders’ Equity			Noncontrolling Interest			Total Equity
	Class A		Class B
Balance as of December 31, 2012	100,086		114,566		$	2,147		$	1,885,836		$	(633,717	)	$	1,254,266		$	10,329		$	1,264,595
Issuance of common stock	20,707		—		207			228,099			—			228,306			—			228,306
Share-based award transactions, net	427		(15	)	4			1,948			—			1,952			3,177			5,129
Repurchase and cancellation of common stock	(28	)	—		—			(287		)	—			(287		)	—			(287		)
Conversion	57,283		(57,283	)	—			—			—			—			—			—
Dividends	—		—		—			—			(98,630		)	(98,630		)	(954		)	(99,584		)
Net income	—		—		—			—			20,199			20,199			353			20,552
Balance as of September 30, 2013	178,475		57,268		$	2,358		$	2,115,596		$	(712,148	)	$	1,405,806		$	12,905		$	1,418,711
Balance as of December 31, 2013	236,880		—		$	2,369		$	2,126,897		$	(742,060	)	$	1,387,206		$	12,543		$	1,399,749
Issuance of common stock	1,542		—		16			17,726			—			17,742			—			17,742
Share-based award transactions, net	508		—		5			3,274			—			3,279			—			3,279
Repurchase and cancellation of common stock	(58	)	—		(1		)	(571		)	—			(572		)	—			(572		)
Redemption of noncontrolling interest	73		—		—			362			—			362			(362		)	—
Dividends	—		—		—			—			(103,097		)	(103,097		)	(854		)	(103,951		)
Net income	—		—		—			—			24,179			24,179			236			24,415
Balance as of September 30, 2014	238,945		—		$	2,389		$	2,147,688		$	(820,978	)	$	1,329,099		$	11,563		$	1,340,662

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

HEALTHCARE TRUST OF AMERICA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2014			2013
Cash flows from operating activities:
Net income	$	24,537		$	20,622
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	101,168			86,654
Share-based compensation expense	3,279			5,129
Bad debt expense	485			107
Gain on sales of real estate	(11,766		)	—
Loss on extinguishment of debt, net	4,663			—
Change in fair value of derivative financial instruments	857			(8,573		)
Changes in operating assets and liabilities:
Receivables and other assets, net	(4,443		)	(13,569		)
Accounts payable and accrued liabilities	13,212			21,928
Security deposits, prepaid rent and other liabilities	(2,442		)	6,377
Net cash provided by operating activities	129,550			118,675
Cash flows from investing activities:
Acquisition of real estate operating properties	(229,644		)	(223,839		)
Proceeds from sales of real estate	40,148			—
Capital expenditures	(24,167		)	(16,486		)
Collection of real estate notes receivable	20,000			—
Issuance of real estate notes receivable	—			(8,520		)
Restricted cash, escrow deposits and other assets	(29,318		)	(2,446		)
Net cash used in investing activities	(222,981		)	(251,291		)
Cash flows from financing activities:
Proceeds from unsecured senior notes	297,615			297,558
Borrowings on unsecured revolving credit facility	213,000			103,000
Payments on unsecured revolving credit facility	(233,000		)	(175,000		)
Payments on secured real estate term loan and mortgage loans	(90,389		)	(155,302		)
Deferred financing costs	(6,093		)	(3,471		)
Derivative financial instrument termination payments	—			(1,195		)
Security deposits	(1,245		)	967
Proceeds from issuance of common stock, net	18,016			229,498
Repurchase and cancellation of common stock	(572		)	(287		)
Dividends	(102,506		)	(95,597		)
Payment on earnout liability	—			(92		)
Distributions to noncontrolling interest of limited partners	(1,061		)	(1,238		)
Net cash provided by financing activities	93,765			198,841
Net change in cash and cash equivalents	334			66,225
Cash and cash equivalents - beginning of period	18,081			15,956
Cash and cash equivalents - end of period	$	18,415		$	82,181

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except unit data)

(Unaudited)

	September 30, 2014			December 31, 2013
ASSETS
Real estate investments:
Land	$	272,922		$	203,001
Building and improvements	2,554,006			2,358,071
Lease intangibles	413,403			411,857
	3,240,331			2,972,929
Accumulated depreciation and amortization	(518,647		)	(445,938		)
Real estate investments, net (see Note 2)	2,721,684			2,526,991
Assets held for sale, net	22,930			—
Real estate notes receivable	8,520			28,520
Cash and cash equivalents	18,415			18,081
Restricted cash and escrow deposits	31,329			18,114
Receivables and other assets, net	141,561			110,285
Other intangibles, net	42,362			50,343
Total assets	$	2,986,801		$	2,752,334
LIABILITIES AND PARTNERS’ CAPITAL
Liabilities:
Debt	$	1,497,136		$	1,214,241
Accounts payable and accrued liabilities	98,163			82,893
Derivative financial instruments - interest rate swaps	4,127			5,053
Security deposits, prepaid rent and other liabilities	31,935			35,339
Intangible liabilities, net	11,520			11,797
Total liabilities	1,642,881			1,349,323
Commitments and contingencies
Redeemable noncontrolling interest of limited partners	1,765			1,717
Partners’ Capital:
Limited partners’ capital, 2,973,998 and 3,052,918 units issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	12,786			13,818
General partners’ capital, 238,944,761 and 236,880,614 units issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	1,329,369			1,387,476
Total partners’ capital	1,342,155			1,401,294
Total liabilities and partners’ capital	$	2,986,801		$	2,752,334

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per unit data)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Revenues:
Rental income	$	95,277		$	82,349		$	274,675		$	235,595
Interest income from real estate notes receivable	257			635			1,834			1,874
Total revenues	95,534			82,984			276,509			237,469
Expenses:
Rental	28,526			25,837			85,179			72,435
General and administrative	5,935			5,980			18,137			18,645
Acquisition-related	2,802			1,403			8,647			3,086
Depreciation and amortization	35,802			29,581			104,346			87,725
Listing	—			—			—			4,405
Total expenses	73,065			62,801			216,309			186,296
Income before other income (expense)	22,469			20,183			60,200			51,173
Other income (expense):
Interest expense:
Interest related to derivative financial instruments	(1,433		)	(1,087		)	(4,148		)	(3,448		)
Net gain (loss) on change in the fair value of derivative financial instruments	2,564			(1,955		)	(857		)	8,573
Total interest related to derivative financial instruments, including net change in the fair value of derivative financial instruments	1,131			(3,042		)	(5,005		)	5,125
Interest related to debt	(14,119		)	(12,146		)	(37,802		)	(35,704		)
Gain on sales of real estate	11,766			—			11,766			—
Loss on extinguishment of debt, net	(5,028		)	—			(4,663		)	—
Other income	1			10			41			28
Net income	$	16,220		$	5,005		$	24,537		$	20,622
Net income attributable to noncontrolling interests (1)	(28		)	(9		)	(106		)	(39		)
Net income attributable to common unitholders	$	16,192		$	4,996		$	24,431		$	20,583
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.07		$	0.02		$	0.10		$	0.09
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.07		$	0.02		$	0.10		$	0.09
Weighted average number of common units outstanding:
Basic	241,948			235,570			241,124			228,188
Diluted	241,948			235,570			241,124			228,188
Distributions declared per common unit	$	0.15		$	0.14		$	0.43		$	0.43
(1) Includes amounts attributable to redeemable noncontrolling interests.

The accompanying notes are an integral part of these condensed consolidated financial statements.

9

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS’ CAPITAL

(In thousands)

(Unaudited)

	General Partners’ Capital					Limited Partners’ Capital					Total Partners’ Capital
	Units		Amount			Units		Amount
Balance as of December 31, 2012	214,652		$	1,254,536		3,056		$	11,663		$	1,266,199
Issuance of general partner units	20,707		228,306			—		—			228,306
Share-based award transactions, net	412		1,952			(2	)	3,177			5,129
Redemptions of general partner units	(28	)	(287		)	—		—			(287		)
Distributions	—		(98,630		)	—		(1,021		)	(99,651		)
Net income attributable to common unitholders	—		20,199			—		384			20,583
Balance as of September 30, 2013	235,743		$	1,406,076		3,054		$	14,203		$	1,420,279
Balance as of December 31, 2013	236,880		$	1,387,476		3,053		$	13,818		$	1,401,294
Issuance of general partner units	1,542		17,742			—		—			17,742
Share-based award transactions, net	508		3,279			(6	)	—			3,279
Redemptions of general partner units	(58	)	(572		)	—		—			(572		)
Redemption of limited partner units	73		362			(73	)	(362		)	—
Distributions	—		(103,097		)	—		(922		)	(104,019		)
Net income attributable to common unitholders	—		24,179			—		252			24,431
Balance as of September 30, 2014	238,945		$	1,329,369		2,974		$	12,786		$	1,342,155

The accompanying notes are an integral part of these condensed consolidated financial statements.

10

HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2014			2013
Cash flows from operating activities:
Net income	$	24,537		$	20,622
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	101,168			86,654
Share-based compensation expense	3,279			5,129
Bad debt expense	485			107
Gain on sales of real estate	(11,766		)	—
Loss on extinguishment of debt, net	4,663			—
Change in fair value of derivative financial instruments	857			(8,573		)
Changes in operating assets and liabilities:
Receivables and other assets, net	(4,443		)	(13,569		)
Accounts payable and accrued liabilities	13,212			21,928
Security deposits, prepaid rent and other liabilities	(2,442		)	6,377
Net cash provided by operating activities	129,550			118,675
Cash flows from investing activities:
Acquisition of real estate operating properties	(229,644		)	(223,839		)
Proceeds from sales of real estate	40,148			—
Capital expenditures	(24,167		)	(16,486		)
Collection of real estate notes receivable	20,000			—
Issuance of real estate notes receivable	—			(8,520		)
Restricted cash, escrow deposits and other assets	(29,318		)	(2,446		)
Net cash used in investing activities	(222,981		)	(251,291		)
Cash flows from financing activities:
Proceeds from unsecured senior notes	297,615			297,558
Borrowings on unsecured revolving credit facility	213,000			103,000
Payments on unsecured revolving credit facility	(233,000		)	(175,000		)
Payments on secured real estate term loan and mortgage loans	(90,389		)	(155,302		)
Deferred financing costs	(6,093		)	(3,471		)
Derivative financial instrument termination payments	—			(1,195		)
Security deposits	(1,245		)	967
Proceeds from issuance of general partner units, net	18,016			229,498
Repurchase and cancellation of general partner units	(572		)	(287		)
Distributions to general partner	(102,506		)	(95,597		)
Payment on earnout liability	—			(92		)
Distributions to limited partners and redeemable noncontrolling interests	(1,061		)	(1,238		)
Net cash provided by financing activities	93,765			198,841
Net change in cash and cash equivalents	334			66,225
Cash and cash equivalents - beginning of period	18,081			15,956
Cash and cash equivalents - end of period	$	18,415		$	82,181

The accompanying notes are an integral part of these condensed consolidated financial statements.

11

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Unless otherwise indicated or unless the context requires otherwise the use of the words “we,” “us” or “our” refers to Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP, collectively.

1. Organization and Description of Business

HTA, a Maryland corporation, and HTALP, a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006. HTA operates as a REIT and is the general partner of HTALP, which is the operating partnership. As of September 30, 2014, HTA owned a 99.0% partnership interest and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the LTIP units) in HTALP. As the sole general partner of HTALP, HTA has the full, exclusive and complete responsibility for HTALP’s day-to-day management and control. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP. As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP, issuing public equity from time to time and guaranteeing certain debts of HTALP. HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity.

HTA is one of the largest publicly-traded REITs focused on medical office buildings in the United States based on gross leasable area (“GLA”). We are primarily focused on acquiring, owning and operating high-quality medical office buildings that are predominantly located on, or aligned with, campuses of nationally or regionally recognized healthcare systems. In addition, we have strong industry relationships, a stable and diversified tenant mix and an extensive and active acquisition network. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we (i) seek internal growth through proactive asset management, leasing and property management oversight, (ii) target mid-sized acquisitions of high-quality medical office buildings in markets with dominant healthcare systems, attractive demographics and that complement our existing portfolio and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage. HTA has qualified to be taxed as a REIT for federal income tax purposes and intends to continue to be taxed as a REIT.

We invest primarily in high-quality medical office buildings in our target markets, and have acquired high-quality medical office buildings and other facilities that serve the healthcare industry with an aggregate purchase price of approximately $3.3 billion through September 30, 2014.

Our principal executive office is located at 16435 North Scottsdale Road, Suite 320, Scottsdale, Arizona, 85254.

2. Summary of Significant Accounting Policies

The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America (“GAAP”), in all material respects, and have been consistently applied in preparing our accompanying condensed consolidated financial statements.

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

12

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2013 Annual Report on Form 10-K.

Variable Interest Entities

As of September 30, 2014, our condensed consolidated financial statements include four VIEs, which we were deemed to be the primary beneficiary. All of the VIEs were established during the third quarter of 2014 to facilitate potential Section 1031 Exchanges. The impact of consolidating the VIEs increased our total real estate assets by $72.2 million, but had no impact on our total assets.

Real Estate Investments

Depreciation expense of buildings and improvements for the three months ended September 30, 2014 and 2013 was $22.6 million and $18.9 million, respectively. Depreciation expense of buildings and improvements for the nine months ended September 30, 2014 and 2013 was $65.0 million and $55.6 million, respectively.

Noncontrolling Interests

HTA’s net income attributable to noncontrolling interests in the accompanying condensed consolidated statements of operations relate to both noncontrolling interest reflected within equity and redeemable noncontrolling interest of limited partners reflected outside of equity in the accompanying condensed consolidated balance sheets. Limited partner units, including LTIP awards, are accounted for as partners’ capital in HTALP’s accompanying condensed consolidated balance sheets and as noncontrolling interest reflected within equity or redeemable noncontrolling interest of limited partners reflected outside of equity in HTA’s accompanying condensed consolidated balance sheets.

Redeemable noncontrolling interests relate to the interests in our consolidated entities that are not wholly owned by us. As these redeemable noncontrolling interests provide for redemption features not solely within our control, we classify such interests outside of permanent equity or partners’ capital.

Recently Issued or Adopted Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Updated (“ASU”) 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360) which changes the requirements for reporting discontinued operations. ASU 2014-08 changes the threshold for disclosing discontinued operations and the related disclosure requirements. Pursuant to ASU 2014-08, only disposals representing a strategic shift, such as a major line of business, a major geographical area or majority equity investment, should be presented as a discontinued operation. If the disposal does qualify as a discontinued operation under ASU 2014-08, the entity will be required to provide expanded disclosures. The guidance will be applied prospectively to new disposals and new classifications of disposal groups held for sale after the effective date. ASU 2014-08 is effective for annual periods beginning on or after December 15, 2014 with early adoption permitted but only for disposals or classifications as held for sale which have not been reported in financial statements previously issued or available for issuance. We adopted ASU 2014-08 as of January 1, 2014 and believe future sales of our individual operating properties will no longer qualify as discontinued operations.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. ASU 2014-09 is effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. We are still evaluating the impact of adopting ASU 2014-09 on our financial statements.

13

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

In June 2014, the FASB issued ASU 2014-12, Compensation - Stock Compensation (Topic 718). ASU 2014-12 requires that a performance target requisite service period be treated as a performance condition and, as a result, this type of performance condition may delay expense recognition until achievement of the performance target is probable. ASU 2014-12 is effective for reporting periods beginning after December 15, 2015, and early adoption is permitted. We will adopt ASU 2014-12 effective January 1, 2016 and it is not anticipated to have a material impact on our financial statements.

3. Business Combinations

For the nine months ended September 30, 2014, we had five acquisitions for an aggregate purchase price of $317.6 million. We incurred $5.6 million of costs attributable to these acquisitions. As part of the acquisitions, we assumed mortgage loans with an aggregate fair value of$91.5 million.

Since the acquisitions were determined to be individually not significant, but material on a collective basis, the allocations for the 2014 acquisitions are set forth below in the aggregate (in thousands):

2014 Acquisitions	Total
Land	$	70,609
Building and improvements	227,458
Below market leasehold interests	98
Above market leases	1,708
In place leases	22,233
Below market leases	(953		)
Above market debt, net	(2,664		)
Net assets acquired	318,489
Other, net	(939		)
Aggregate purchase price	$	317,550

The weighted average lives of the above acquired intangible assets and liabilities were 9.1 years and 8.5 years, respectively.

The following is a brief description of each of the acquisitions.

• In June 2014, we acquired a portfolio of medical office buildings located in Boston, Massachusetts; Miami, Florida; and Baltimore, Maryland, for an aggregate purchase price of $200.0 million.

• In June 2014, we acquired a medical office building located in Raleigh, North Carolina for $11.5 million.

• In August 2014, we acquired a portfolio of medical office buildings located in White Plains, New York for $64.0 million.

• In August 2014, we acquired a medical office building located in Charleston, South Carolina for $24.8 million.

• In September 2014, we acquired a medical office building located in Clearwater, Florida for $17.3 million.

14

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The acquisitions completed during the nine months ended September 30, 2013 were determined to be individually not significant, but material on a collective basis. The allocations for these acquisitions are set forth below in the aggregate (in thousands):

2013 Acquisitions	Total
Land	$	13,415
Building and improvements	175,039
Below market leasehold interests	1,836
Above market leases	1,987
In place leases	32,205
Tenant relationships	16,541
Below market leases	(1,167		)
Above market debt	(241		)
Net assets acquired	239,615
Other, net	2,299
Aggregate purchase price	$	241,914

The weighted average lives of the above acquired intangible assets and liabilities were 7.4 years and 5.7 years, respectively.

4. Dispositions and Assets Held for Sale

During the three months ended September 30, 2014, we had two dispositions of portfolios of medical office buildings for an aggregate gross sales price of $42.0 million resulting in a gain of $11.8 million.  In addition, we entered into a purchase and sale agreement as the seller and received a non-refundable deposit from the purchaser for the sale of an additional portfolio of medical office buildings for gross proceeds of $40.9 million.  This portfolio, which includes $18.9 million of real estate investments and $3.1 million of other intangibles, was reclassified to assets held for sale during the third quarter of 2014.  Our sale of these medical office buildings closed in October 2014 resulting in a gain of approximately $16 million. 

During 2013, we had one property within our portfolio that met the criteria for classification as held for sale. Accordingly, we presented the assets and liabilities separately and included the results of operations within discontinued operations for all periods presented. Additionally, we ceased recording depreciation and amortization following the held for sale designation. During the quarter ended March 31, 2014, we determined that it was appropriate to reclassify the property out of held for sale in our condensed consolidated balance sheets and to include the results of operations within the results of operations of our operating properties in our condensed consolidated statements of operations for all periods presented as the property no longer met the criteria for classification as held for sale. We measured the property to be reclassified at the lower of its carrying value before it was classified as held for sale (adjusted for any depreciation and amortization expense that would have been recognized had the property been continuously classified as held and used) or its fair value at the date of the subsequent decision not to sell. As such, during the quarter ended March 31, 2014, we recorded $0.8 million of depreciation and amortization expense which represents the depreciation and amortization on the property that was not recorded when it was classified as held for sale.

5. Real Estate Notes Receivable

As of December 31, 2013, we had $28.5 million in real estate notes receivable secured by medical office buildings. During the nine months ended September 30, 2014, $20.0 million of our real estate notes receivable were repaid by the borrower. As of September 30, 2014, we had two promissory notes outstanding totaling an aggregate amount of $8.5 million. Each of the promissory notes has an interest rate of 7.0% per annum and mature on October 1, 2016. We are advised by the property owner/borrower that the properties are being actively marketed for sale and the outstanding notes will be repaid upon sale.

We monitor the credit quality of our real estate notes receivable on an ongoing basis by tracking possible credit quality indicators. As of September 30, 2014, our real estate notes receivable are current and we have not provided for any allowance for losses or recorded any impairments. We made no purchases or sales of real estate notes receivable during the nine months ended September 30, 2014.

15

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

6. Intangible Assets and Liabilities

Intangible assets and liabilities consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands, except weighted average remaining amortization period):

	September 30, 2014				December 31, 2013
	Balance			Weighted Average Remaining Amortization Period in Years	Balance			Weighted Average Remaining Amortization Period in Years	Balance Sheet Classification
Assets:
In place leases	$	225,023		8.6	$	213,338		8.8	Lease intangibles
Tenant relationships	188,380			10.4	198,519			10.5	Lease intangibles
Above market leases	26,566			5.8	26,799			6.3	Other intangibles, net
Below market leasehold interests	31,393			67.7	37,640			68.9	Other intangibles, net
	471,362				476,296
Accumulated amortization	(172,708		)		(151,860		)
Total	$	298,654		15.4	$	324,436		15.9
Liabilities:
Below market leases	$	13,999		12.1	$	13,989		12.4	Intangible liabilities, net
Above market leasehold interests	3,827			32.4	3,827			33.1	Intangible liabilities, net
	17,826				17,816
Accumulated amortization	(6,306		)		(6,019		)
Total	$	11,520		18.1	$	11,797		18.4

The following is a summary of the net intangible amortization for the three and nine months ended September 30, 2014 and 2013 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Amortization recorded against rental income related to above or below market leases	$	505	$	417	$	1,534	$	1,298
Rental expense related to above or below market leasehold interests	112		89		358		278
Amortization expense related to in place leases and tenant relationships	12,066		9,955		36,247		29,970

7. Receivables and Other Assets

Receivables and other assets consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014		December 31, 2013
Accounts and other receivables, net	$	23,749	$	22,847
Tenant note receivable	3,080		3,173
Deferred financing costs, net	12,418		10,921
Deferred leasing costs, net	16,616		13,500
Lease inducements, net	807		771
Straight-line rent receivables, net	54,057		47,317
Prepaid expenses, deposits, equipment and other, net	27,544		6,683
Derivative financial instruments - interest rate swaps	3,290		5,073
Total	$	141,561	$	110,285

16

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following is a summary of amortization of deferred leasing costs, deferred financing costs, and lease inducements for the three and nine months ended September 30, 2014 and 2013 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Amortization expense related to deferred leasing costs	$	957	$	686	$	2,646	$	1,862
Interest expense related to deferred financing costs	724		805		2,319		3,084
Amortization recorded against rental income related to lease inducements	50		56		168		173

8. Debt

Debt consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014			December 31, 2013
Unsecured revolving credit facility	$	35,000		$	55,000
Unsecured term loans	455,000			455,000
Unsecured senior notes	600,000			300,000
Fixed rate mortgages	379,196			373,751
Variable rate mortgages	29,590			29,925
	1,498,786			1,213,676
Net premium (discount)	(1,650		)	565
Total	$	1,497,136		$	1,214,241

Unsecured Credit Agreement

Unsecured Revolving Credit Facility

HTA’s and HTALP’s $650.0 million unsecured revolving credit facility matures on March 29, 2016 and includes a one-year extension, at the option of the borrower, subject to certain conditions. The actual amount of credit available to us is a function of certain loan-to-value and debt service coverage ratios set forth in the credit facility. The maximum principal amount of the credit facility may be increased, subject to additional financing being provided by our existing lenders or new lenders being added to the unsecured revolving credit facility.

Borrowings under the $650.0 million unsecured revolving credit facility accrue interest equal to adjusted LIBOR, plus a margin ranging from 1.10% to 1.75% per annum based on our credit rating. We also pay a facility fee ranging from 0.20% to 0.50% per annum on the aggregate commitments under the unsecured revolving credit facility. As of September 30, 2014, the margin associated with our borrowings was 1.30% per annum and the facility fee was 0.25% per annum.

Unsecured Term Loan

On January 7, 2014, HTA and HTALP executed an amendment to the unsecured credit agreement that decreased the interest rate on the unsecured term loan and extended the maturity date. Borrowings under the $300.0 million unsecured term loan accrue interest equal to adjusted LIBOR, plus a margin ranging from 1.05% to 1.95% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2014 was 1.20% per annum. We have interest rate swaps in place that fix the interest rate at 2.30% per annum, based on our current credit rating. The unsecured term loan matures on January 31, 2018 and includes a one-year extension, at the option of the borrower, subject to certain conditions.

$155.0 Million Unsecured Term Loan

On July 20, 2012, HTALP entered into a $155.0 million unsecured term loan that is guaranteed by HTA. The loan matures on July 19, 2019 and the interest rate thereon is equal to LIBOR, plus a margin ranging from 1.55% to 2.40% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2014 was 1.70% per annum. We have interest rate swaps in place that fix the interest rate at 2.99% per annum, based on our current credit rating. The maximum principal amount under this unsecured term loan may be increased by us, subject to such additional financing being provided by our existing lender.

17

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

$300.0 Million Unsecured Senior Notes due 2023

On March 28, 2013, HTALP issued $300.0 million of unsecured senior notes guaranteed by HTA that mature on April 15, 2023. The unsecured senior notes are registered under the Securities Act of 1933, as amended (the “Securities Act”), bear interest at 3.70% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.186% of the principal amount thereof, with an effective yield to maturity of 3.80% per annum.

$300.0 Million Unsecured Senior Notes due 2021

On June 26, 2014, HTALP issued $300.0 million of unsecured senior notes guaranteed by HTA that mature on July 15, 2021. The unsecured senior notes are registered under the Securities Act, bear interest at 3.375% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.205% of the principal amount thereof, with an effective yield to maturity of 3.50% per annum.

Fixed and Variable Rate Mortgages

As of September 30, 2014, HTALP and its subsidiaries had fixed and variable rate mortgages with interest rates ranging from 1.60% to 12.75% per annum and a weighted average interest rate of 5.31% per annum. Including the impact of the interest rate swap associated with our variable rate mortgage, the weighted average interest rate was 5.56% per annum. During 2014, we assumed certain fixed rate mortgage loans, see Note 3.

Future Debt Maturities

The following table summarizes the debt maturities and scheduled principal repayments as of September 30, 2014 (in thousands):

Year	Amount
2014	$	2,105
2015	73,454
2016	104,625
2017	102,744
2018	314,881
Thereafter	900,977
Total	$	1,498,786

The above scheduled debt maturities do not include the extensions available to us under the unsecured credit agreement as discussed above.

We are required by the terms of our applicable debt agreements to meet various affirmative and negative covenants that we believe are customary for these types of facilities, such as limitations on the incurrence of debt by us, and our subsidiaries that own unencumbered assets, limitations on the nature of HTALP’s business, and limitations on distributions by HTALP and its subsidiaries that own unencumbered assets. Our debt agreements also impose various financial covenants on us, such as a maximum ratio of total indebtedness to total asset value, a minimum ratio of EBITDA to fixed charges, a minimum tangible net worth covenant, a maximum ratio of unsecured indebtedness to unencumbered asset value, rent coverage ratios, and a minimum ratio of unencumbered net operating income to unsecured interest expense. As of September 30, 2014, we believe that we were in compliance with all such financial covenants and reporting requirements. In addition, certain of our debt agreements include events of default provisions that we believe are customary for these types of facilities, including restricting HTA from making dividend distributions to its stockholders in the event HTA is in default thereunder, except to the extent necessary for HTA to maintain its REIT status.

18

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

9. Derivative Financial Instruments

The following table lists the derivative financial instrument assets and (liabilities) held by us as of September 30, 2014 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	200,000	LIBOR	1.23	%	$	(1,404	)	Swap	3/29/2017
100,000		LIBOR	0.86		(465		)	Swap	6/15/2016
50,000		LIBOR	1.39		812			Swap	7/17/2019
105,000		LIBOR	1.24		2,478			Swap	7/17/2019
27,062		LIBOR	4.98		(2,258		)	Swap	5/1/2020

The following table lists the derivative financial instrument assets and (liabilities) held by us as of December 31, 2013 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	200,000	LIBOR	1.23	%	$	(2,078	)	Swap	3/29/2017
100,000		LIBOR	0.86		(729		)	Swap	6/15/2016
50,000		LIBOR	1.39		1,350			Swap	7/17/2019
105,000		LIBOR	1.24		3,723			Swap	7/17/2019
27,618		LIBOR	4.98		(2,246		)	Swap	5/1/2020

As of September 30, 2014 and December 31, 2013, the gross fair value of our derivative financial instruments was as follows (in thousands):

	Asset Derivatives					Liability Derivatives
		Fair Value					Fair Value
Derivatives Not Designated as Hedging Instruments:	Balance Sheet Location	September 30, 2014		December 31, 2013		Balance Sheet Location	September 30, 2014		December 31, 2013
Interest rate swaps	Receivables and other assets	$	3,290	$	5,073	Derivative financial instruments	$	4,127	$	5,053

There were no derivatives offset in our accompanying condensed consolidated balance sheets as of September 30, 2014 and December 31, 2013. As of September 30, 2014 and December 31, 2013, we had derivatives subject to enforceable master netting arrangements which allowed for net cash settlement with the respective counterparties (in thousands):

	September 30, 2014							December 31, 2013
	Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts		Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts
Asset derivatives	$	3,290	$	(1,404	)	$	1,886	$	5,073	$	(2,078	)	$	2,995
Liability derivatives	4,127		(1,404		)	2,723		5,053		(2,078		)	2,975

We have agreements with each of our interest rate swap derivative counterparties that contain a provision whereby if we default on certain of our unsecured indebtedness, then our counterparties could declare us in default on our interest rate swap derivative obligations resulting in an acceleration of the indebtedness. In addition, we are exposed to credit risk in the event of non-performance by our derivative counterparties. We believe we mitigate the credit risk by entering into agreements with credit-worthy counterparties. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, our fair value of interest rate swap derivative liabilities is adjusted to reflect the impact of our credit quality. As of September 30, 2014, there have been no termination events or events of default related to our interest rate swaps.

19

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

10. Commitments and Contingencies

Litigation

We are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material effect on our condensed consolidated financial position, results of operations or cash flows.

Environmental Matters

We follow the policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency.

Other

Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material effect on our condensed consolidated financial position, results of operations or cash flows.

11. Stockholders’ Equity and Partners’ Capital

HTALP’s partnership agreement provides that it will distribute cash flows from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner determines. Except for certain LTIP units that have not vested, dividend distributions are made such that a holder of one partnership unit will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of HTA’s common stock. In addition, for each share of common stock issued or redeemed by HTA, HTALP issues or redeems a corresponding number of partnership units.

Common Stock Offerings

On February 28, 2014, HTA amended the at-the-market (“ATM”) offering program of its common stock with an aggregate sales price of up to $300.0 million primarily to add sales agents to the program. During the nine months ended September 30, 2014, HTA issued and sold 1,541,715 shares of common stock, at an average price of $11.86 per share and, as of September 30, 2014, $281.7 million remained available for issuance under the ATM.

Common Stock Dividends

See condensed consolidated statements of operations for the dividends declared during the three and nine months ended September 30, 2014 and 2013. On October 28, 2014, HTA declared a quarterly cash dividend of $0.145 per share to be paid onJanuary 6, 2015 to stockholders of record of its common stock on December 29, 2014.

Incentive Plan

HTA’s Amended and Restated 2006 Incentive Plan (the “Plan”) permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors or the Compensation Committee. The Plan authorizes the granting of awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 10,000,000. As of September 30, 2014, there were 4,594,200 awards available for grant under the Plan.

20

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

LTIP Units

Awards under the LTIP consist of Series C units in HTALP, and are subject to the achievement of certain performance and market conditions in order to vest. Once vested, the Series C units are converted into common units of HTALP, which may be converted into shares of HTA’s common stock. For thethree and nine months ended September 30, 2013, we recognized compensation expense related to LTIP awards of$0.0 millionand$3.1 million, respectively, which was recorded in listing expenses. The LTIP awards were fully expensed in 2013, except for approximately$4.5 millionof expense associated with450,000units that will only vest in the event of a change in control. We will not recognize any expense associated with these units until such time as a change in control event occurs or is probable.

The following is a summary of the activity in our LTIP units during 2014:

	LTIP Units		Weighted Average Grant Date Fair Value
Balance as of December 31, 2013	516,500		$	9.43
Granted	—		—
Vested	—		—
Forfeited	(6,020	)	5.62
Balance as of September 30, 2014	510,480		$	9.47

Restricted Common Stock

For the three and nine months ended September 30, 2014, we recognized compensation expense of $1.0 million and $3.3 million, respectively, which was recorded in general and administrative expenses. For the three months ended September 30, 2013, we recognized compensation expense of $0.5 million, which was recorded in general and administrative expenses. For the nine months ended September 30, 2013, we recognized compensation expense of $2.0 million, of which $1.4 million was recorded in general and administrative expenses and $0.6 million was recorded in listing expenses.

As of September 30, 2014, there was approximately $5.2 million of unrecognized compensation expense net of estimated forfeitures, which will be recognized over a remaining weighted average period of 2.0 years.

The following is a summary of the activity in our restricted common stock during 2014:

	Restricted Common Stock		Weighted Average Grant Date Fair Value
Balance as of December 31, 2013	641,000		$	10.34
Granted	563,200		10.21
Vested	(148,000	)	10.07
Forfeited	(55,600	)	9.96
Balance as of September 30, 2014	1,000,600		$	10.46

12. Fair Value of Financial Instruments

Financial Instruments Reported at Fair Value

The table below presents our assets and liabilities measured at fair value on a recurring basis as of September 30, 2014, aggregated by the applicable Level in the fair value hierarchy (in thousands):

	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1 )		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Derivative financial instruments	$	—	$	3,290	$	—	$	3,290
Liabilities:
Derivative financial instruments	$	—	$	4,127	$	—	$	4,127

21

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2013, aggregated by the applicable Level in the fair value hierarchy (in thousands):

	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1 )		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Derivative financial instruments	$	—	$	5,073	$	—	$	5,073
Liabilities:
Derivative financial instruments	$	—	$	5,053	$	—	$	5,053

There have been no transfers of assets or liabilities between Levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our interest rate swap derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our interest rate swap derivative positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our interest rate swap derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Financial Instruments Disclosed at Fair Value

We consider the carrying values of cash and cash equivalents, accounts and other receivables, restricted cash and escrow deposits, and accounts payable and accrued liabilities to approximate fair value for these financial instruments because of the short period of time between origination of the instruments and their expected realization. All of these financial instruments are considered Level 2. The fair value of the real estate notes receivable and tenant note receivable are estimated by discounting the expected cash flow on the notes at current rates for loans with similar maturities. The fair value of debt is estimated using borrowing rates available to us with similar terms and maturities. The following table sets forth the carrying value and fair value of our real estate notes receivable, tenant note receivable and debt (in thousands):

		September 30, 2014				December 31, 2013
	Fair Value Level	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Real estate notes receivable	2	$	8,520	$	8,520	$	28,520	$	28,520
Tenant note receivable	2	3,080		3,028		3,173		3,013
Debt	2	1,497,136		1,509,761		1,214,241		1,237,699

22

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

13. Per Share Data of HTA

HTA includes unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents as “participating securities” pursuant to the two-class method. The resulting classes are our common stock and restricted stock. For the three and nine months ended September 30, 2014 and 2013, all of HTA’s earnings were distributed and the calculated earnings per share amount would be the same for all classes. The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA common stock for the three and nine months ended September 30, 2014 and 2013 (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Numerator:
Net income	$	16,220		$	5,005		$	24,537		$	20,622
Net income attributable to noncontrolling interests	(188		)	(182		)	(358		)	(423		)
Net income attributable to common stockholders	$	16,032		$	4,823		$	24,179		$	20,199
Denominator:
Weighted average number of shares outstanding - basic	238,968			232,514			238,099			225,132
Dilutive shares	2,464			2,509			2,509			1,639
Weighted average number of shares outstanding - diluted	241,432			235,023			240,608			226,771
Earnings per common share - basic
Net income attributable to common stockholders	$	0.07		$	0.02		$	0.10		$	0.09
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.07		$	0.02		$	0.10		$	0.09

14. Per Unit Data of HTALP

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and nine months ended September 30, 2014 and 2013 (in thousands, except per unit data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Numerator:
Net income	$	16,220		$	5,005		$	24,537		$	20,622
Net income attributable to noncontrolling interests	(28		)	(9		)	(106		)	(39		)
Net income attributable to common unitholders	$	16,192		$	4,996		$	24,431		$	20,583
Denominator:
Weighted average number of units outstanding - basic	241,948			235,570			241,124			228,188
Dilutive units	—			—			—			—
Weighted average number of units outstanding - diluted	241,948			235,570			241,124			228,188
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.07		$	0.02		$	0.10		$	0.09
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.07		$	0.02		$	0.10		$	0.09

23

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

15. Supplemental Cash Flow Information

The following is the supplemental cash flow information for the nine months ended September 30, 2014 and 2013 (in thousands):

	Nine Months Ended September 30,
	2014		2013
Interest paid	$	29,758	$	27,743
Income taxes paid	757		904
Supplemental Disclosure of Noncash Activities:
The following represents the significant increase (decrease) in certain assets and liabilities in connection with our acquisitions:
Debt and interest rate swaps	$	88,845	$	17,982
Financing Activities:
Dividend distributions declared, but not paid	$	34,652	$	34,238

24

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The use of the words “we,” “us” or “our” refers to HTA and HTALP, collectively.

The following discussion should be read in conjunction with our condensed consolidated financial statements and notes appearing elsewhere in this Quarterly Report on Form 10-Q, as well as with the audited consolidated financial statements, accompanying notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2013 Annual Report on Form 10-K. Such condensed consolidated financial statements and information have been prepared to reflect HTA’s and HTALP’s financial position as of September 30, 2014 and December 31, 2013, together with results of operations and cash flows for the three and nine months ended September 30, 2014 and 2013.

The information set forth below is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations.

• Forward-Looking Statements;

• Executive Summary;

• Company Highlights;

• Interim Unaudited Financial Data;

• Critical Accounting Policies;

• Recently Issued or Adopted Accounting Pronouncements;

• Factors Which May Influence Results of Operations;

• Results of Operations;

• Non-GAAP Financial Measures;

• Liquidity and Capital Resources;

• Commitments and Contingencies;

• Debt Service Requirements;

• Off-Balance Sheet Arrangements;

• Inflation; and

• Federal Income Tax Changes and Updates for Incorporation in Existing Registration Statements.

Forward-Looking Statements

Certain statements contained in this Quarterly Report on Form 10-Q constitute forward-looking statements within the meaning of the safe harbor from civil liability provided for such statements by the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”)). Such statements include, in particular, statements about our plans, strategies and prospects and estimates regarding future medical office building market performance. Additionally, such statements are subject to certain risks and uncertainties, as well as known and unknown risks, which could cause actual results to differ materially and in adverse ways from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of our performance in future periods. Forward-looking statements are generally identifiable by the use of such terms as “expect,” “project,” “may,” “should,” “could,” “would,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “opinion,” “predict,” “potential,” “pro forma” or the negative of such terms and other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this Quarterly Report on Form 10-Q is filed with the SEC. We cannot guarantee the accuracy of any such forward-looking statements contained in this Quarterly Report on Form 10-Q, and we do not intend to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Any such forward-looking statements reflect our current views about future events, are subject to unknown risks, uncertainties, and other factors, and are based on a number of assumptions involving judgments with respect to, among other things, future economic, competitive and market conditions, all of which are difficult or impossible to predict accurately. To the extent that our assumptions differ from actual results, our ability to meet such forward-looking statements, including our ability to generate positive cash flow from operations, provide dividends to stockholders, and maintain the value of our real estate properties, may be significantly hindered. Factors that might impair our ability to meet such forward-looking statements include, without limitation, those discussed in Part I, Item 1A - Risk Factors in our 2013 Annual Report on Form 10-K, which is incorporated by reference herein.

25

Forward-looking statements express expectations of future events. All forward-looking statements are inherently uncertain as they are based on various expectations and assumptions concerning future events and they are subject to numerous known and unknown risks and uncertainties that could cause actual events or results to differ materially from those projected. Due to these inherent uncertainties, our stockholders are urged not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date made. In addition, we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to projections over time, except as required by law.

These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. Additional information concerning us and our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Executive Summary

HTA conducts substantially all of its operations through HTALP. HTA is one of the largest publicly-traded REITs focused on medical office buildings in the United States based on GLA. We are primarily focused on acquiring, owning and operating high-quality medical office buildings that are predominantly located on, or aligned with, campuses of nationally or regionally recognized healthcare systems. In addition, we have strong industry relationships, a stable and diversified tenant mix, and an extensive and active acquisition network. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments and to provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective (i) we seek internal growth through proactive asset management, leasing and property management, (ii) target mid-sized acquisitions of high-quality on-campus or aligned medical office buildings in markets with dominant healthcare systems, attractive demographics and that complement our existing portfolio, and (iii) actively manage our balance sheet to maintain flexibility with low leverage.

We invest primarily in high-quality medical office buildings located in our target markets. As of September 30, 2014, our portfolio consisted primarily of medical office buildings with an aggregate purchase price of $3.3 billion, including approximately 14.6 million square feet of GLA throughout the United States. The leased rate for our portfolio was 91.8% (includes leases which have been executed, but which have not yet commenced) and the occupancy rate was 91.1% as of September 30, 2014. Approximately 96% of our portfolio, based on GLA, is located on, or aligned with, campuses of nationally or regionally recognized healthcare systems. We continue to focus on building relationships with strong tenants and healthcare systems that are leaders in their markets. As of September 30, 2014, approximately 58% of our annualized base rent was derived from tenants that have (or whose parent companies have) a credit rating from a nationally recognized rating agency.

Our portfolio is diversified geographically across 27 states, with no state having more than 13% of our total GLA as of September 30, 2014. We are concentrated in locations that we have determined to be strategic based on demographic trends and projected demand for medical office buildings, and we expect to continue to invest in these markets. We have concentrations in the following key markets: Phoenix, Arizona; Pittsburgh, Pennsylvania; Greenville, South Carolina; Albany, New York; Indianapolis, Indiana; Houston, Texas; Dallas, Texas; Atlanta, Georgia; Miami, Florida; Boston, Massachusetts; Denver, Colorado and Raleigh, North Carolina.

Company Highlights

Portfolio Operating Performance

• For the three months ended September 30, 2014, we had net income of $16.2 million, as compared to $5.0 million for the three months ended September 30, 2013. For the nine months ended September 30, 2014, we had net income of $24.5 million, as compared to $20.6 million for the nine months ended September 30, 2013.

• For the three months ended September 30, 2014, HTA’s Normalized FFO was $0.19 per diluted share, or $45.5 million, an increase of $0.03 per diluted share, or 19%, as compared to the three months ended September 30, 2013. For the three months ended September 30, 2014, HTALP’s Normalized FFO was $0.19 per diluted unit, or $45.5 million, an increase of $0.03 per diluted unit, or 19%, as compared to the three months ended September 30, 2013.

• For the nine months ended September 30, 2014, HTA’s Normalized FFO was $0.55 per diluted share, or $131.4 million, an increase of $0.07 per diluted share, or 15%, as compared to nine months ended September 30, 2013. For the nine months ended September 30, 2014, HTALP’s Normalized FFO was $0.54 per diluted unit, or $131.4 million, an increase of $0.07 per diluted unit, or 15%, as compared to the nine months ended September 30, 2013.

• For additional information on Normalized FFO, see “FFO and Normalized FFO” below, which includes a reconciliation to net income or loss attributable to common stockholders/unitholders and an explanation of why we present this non-GAAP financial measure.

26

• For the three months ended September 30, 2014, our total revenue increased 15.1%, or $12.6 million, to $95.5 million, as compared to the three months ended September 30, 2013. For the nine months ended September 30, 2014, our total revenue increased 16.4%, or $39.0 million, to $276.5 million, as compared to the nine months ended September 30, 2013.

• For the three months ended September 30, 2014, Net Operating Income (“NOI”) increased 17.3%, or $9.9 million, to $67.0 million, as compared to the three months ended September 30, 2013. For the nine months ended September 30, 2014, NOI increased 15.9%, or $26.3 million, to $191.3 million, as compared to the nine months ended September 30, 2013.

• For the three months ended September 30, 2014, our Same-Property Cash NOI increased 3.1%, or $1.6 million, to $54.0 million, as compared to the three months ended September 30, 2013. For the nine months ended September 30, 2014, our Same-Property Cash NOI increased 3.0%, or $4.5 million, to $154.9 million, as compared to the nine months ended September 30, 2013.

• With respect to the last two bullets above, for additional information on NOI and Same-Property Cash NOI, see “NOI, Cash NOI and Same-Property Cash NOI” below, which includes a reconciliation to net income or loss and an explanation of why we present these non-GAAP financial measures.

Relationship-Focused Strategy

We have been one of the most active investors in the medical office sector over the last seven years and have developed significant industry relationships with health systems, physician practices, and regional medical office developers and management firms.

• We have acquired $317.6 million of medical office buildings to date in 2014, an increase in our portfolio size by approximately 10.6% based on purchase price.

• All of our 2014 acquisitions to date are either on campus or affiliated with health systems, with 60% of the properties acquired located directly on or adjacent to health system campuses. The leased rate at closing of these acquired properties was approximately 96%.

• Approximately 60% of our 2014 acquisitions to date by GLA were located in our target markets of Boston, Charleston, Miami and Raleigh. The remaining properties were located in markets of Baltimore, Clearwater and White Plains.

• During the three months ended September 30, 2014, we initiated our asset recycling program and sold two portfolios of medical office buildings for an aggregate gross sales price of $42.0 million. These dispositions generated gains of $11.8 million.

Internal Growth through Proactive Asset Management Leasing and Property Management

• As of September 30, 2014, our leased rate (includes leases which have been executed, but which have not yet commenced) was 91.8% by GLA and our occupancy rate was 91.1% by GLA.

• During the three and nine months ended September 30, 2014, we entered into new or renewal leases on approximately 555,000 and 1.3 million square feet of GLA, respectively.

• Tenant retention for the portfolio was approximately 85% for the quarter and 83% for the year-to-date, which we believe is indicative of our commitment to maintaining high-quality buildings in desirable locations and fostering strong tenant relationships. Tenant retention is calculated by taking the sum of the total GLA of tenants that renew an expiring lease divided by the total GLA of expiring leases.

• During the three and nine months ended September 30, 2014, we expanded our in-house property management and leasing platform by approximately 258,000 and 1.5 million square feet of GLA, respectively. As of September 30, 2014, our in-house property management and leasing platform operated 13.3 million square feet, or 91% of our total GLA.

27

Financial Strategy and Balance Sheet Flexibility

• As of September 30, 2014, we had total liquidity of $627.9 million, including cash and cash equivalents of $18.4 million and $609.5 million available on our unsecured revolving credit facility. Our leverage ratio of debt to total capitalization was 34.8%.

• Thus far in 2014, HTA has issued and sold approximately $18.3 million of common stock through the equity ATM program, at an average price of $11.86 per share.

• In January 2014, we amended our $300.0 million term loan to extend the initial maturity to January 2018, and to decrease the interest rate to LIBOR plus 1.2% based on our current credit rating, a decrease of 35 basis points.

• In May 2014, Standard & Poor’s Rating Services (“Standard & Poor’s”) upgraded HTA’s investment grade credit rating with a stable outlook.

• In June 2014, we issued and sold $300.0 million of 7-year unsecured senior notes at an interest rate of 3.375% per annum.

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2013 Annual Report on Form 10-K.

Critical Accounting Policies

The complete list of our critical accounting policies was disclosed in our 2013 Annual Report on Form 10-K. There have been no material changes to our critical accounting policies as disclosed therein.

Recently Issued or Adopted Accounting Pronouncements

See Note 2 to our accompanying condensed consolidated financial statements for a discussion of recently issued or adopted accounting pronouncements.

Factors Which May Influence Results of Operations

We are not aware of any material trends or uncertainties, other than national economic conditions affecting real estate generally and the risk factors previously listed in Part I, Item 1A - Risk Factors, in our 2013 Annual Report on Form 10-K, that may reasonably be expected to have a material impact, favorable or unfavorable, on revenues or income from the acquisition, management and operation of our properties.

Rental Income

The amount of rental income generated by our properties depends principally on our ability to maintain the occupancy rates of currently leased space and to lease currently available space and space that will become available from unscheduled lease terminations at the then applicable rental rates. Negative trends in one or more of these factors could adversely affect our rental income in future periods.

Acquisitions and Dispositions

During the nine months ended September 30, 2014, we had five acquisitions for an aggregate purchase price of $317.6 million. During the three months ended September 30, 2014, we had two dispositions of portfolios of medical office buildings for an aggregate gross sales price of $42.0 million. The amount of any future acquisitions or dispositions could have a significant impact on our results of operations in future periods.

28

Results of Operations

Comparison of the Three and Nine Months Ended September 30, 2014 and 2013

As of September 30, 2014, we owned and operated approximately 14.6 million square feet of GLA with a 91.8% leased rate (includes leases which have been executed, but which have not yet commenced) and a 91.1% occupancy rate. As of September 30, 2013, we owned and operated approximately 13.6 million square feet of GLA with a 91.4% leased rate (includes leases which have been executed, but which have not yet commenced) and a 90.7% occupancy rate. All explanations are applicable to both HTA and HTALP unless otherwise noted.

NOI and Same-Property Cash NOI

NOI increased $9.9 million to $67.0 million for the three months ended September 30, 2014, as compared to the three months ended September 30, 2013. This increase was primarily due to the $9.0 million of additional NOI from our 2013 and 2014 acquisitions. NOI increased $26.3 million to $191.3 million for the nine months ended September 30, 2014, as compared to the nine months ended September 30, 2013. This increase was primarily due to the $23.3 million of additional NOI from our 2013 and 2014 acquisitions.

Same-Property Cash NOI increased $1.6 million to $54.0 million for the three months ended September 30, 2014, as compared to the three months ended September 30, 2013. Same-Property Cash NOI increased $4.5 million to $154.9 million for the nine months ended September 30, 2014, as compared to the nine months ended September 30, 2013. The increase was primarily the result of rent escalations and an increase in occupancy for both the three and nine months ended September 30, 2014.

Rental Income

For the three and nine months ended September 30, 2014 and 2013, rental income was comprised of the following (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Contractual rental income and other operating revenue (1)	$	92,276	$	80,313	$	267,068	$	229,268
Straight-line rent	3,001		2,036		7,607		6,327
Total	$	95,277	$	82,349	$	274,675	$	235,595
(1) Includes tenant recoveries and amortization of above and below market leases.

Contractual rental income and other operating revenue increased $12.0 million for the three months ended September 30, 2014, as compared to the three months ended September 30, 2013. The increase was primarily due to $11.4 million of additional contractual rental income from our 2013 and 2014 acquisitions and contractual rent increases. For the three months ended September 30, 2014, we entered into new and renewal leases on approximately 555,000 square feet of GLA. The new and renewal leases commenced at an average annual base rent of $19.93 per square foot of GLA compared to $19.95 per square foot of GLA for expiring leases measured on a consistent basis.  Leases that expired in the quarter had rents that were generally at market rates.  Generally, leasing concessions vary depending on lease type and term. For the three months ended September 30, 2014, new leases had tenant improvements, leasing commissions and tenant concessions of $25.41, $4.72 and $6.43 per square foot of GLA, respectively, compared to $24.50, $5.07 and $4.98 per square foot of GLA, respectively, for the three months ended September 30, 2013.  Renewal leases had tenant improvements, leasing commissions and tenant concessions of $9.63, $2.99 and $0.80 per square foot of GLA, respectively, for the three months ended September 30, 2014 compared to $4.35, $2.00 and $3.00, respectively, for the three months ended September 30, 2013.

Contractual rental income and other operating revenue increased $37.8 million for the nine months ended September 30, 2014, as compared to the nine months ended September 30, 2013. The increase was primarily due to $32.4 million of additional contractual rental income from the 2013 and 2014 acquisitions and contractual rent increases. For the nine months ended September 30, 2014, we entered into new and renewal leases of approximately 1.3 million square feet of GLA. The new and renewal leases commenced at an average annual base rent of $20.65 per square foot of GLA compared to $20.90 per square foot of GLA for expiring leases measured on a consistent basis. Leases that have expired thus far in 2014 had rents that were generally at market rates. Generally, leasing concessions vary depending on lease type and term. For the nine months ended September 30, 2014, new leases had tenant improvements, leasing commissions and tenant concessions of $19.25, $4.19 and $5.37 per square foot of GLA, respectively, compared to $20.43, $5.47 and $3.70 per square foot of GLA, respectively, for the nine months ended September 30, 2013. Renewal leases had tenant improvements, leasing commissions and tenant concessions of $7.30, $2.62 and $1.42 per square foot of GLA, respectively, for the nine months ended September 30, 2014 compared to $4.16, $2.17 and $1.14, respectively, for the nine months ended September 30, 2013.

29

Rental Expenses

For the three months ended September 30, 2014 and 2013, rental expenses attributable to our properties were $28.5 million and $25.8 million, respectively. For the nine months ended September 30, 2014 and 2013, rental expenses attributable to our properties were $85.2 million and $72.4 million, respectively. The increase in rental expenses is primarily due to the $3.3 million and $11.6 million of additional rental expenses associated with the 2013 and 2014 acquisitions for the three and nine months ended September 30, 2014, respectively.

General and Administrative Expenses

For the three months ended September 30, 2014 and 2013, general and administrative expenses were $5.9 million and $6.0 million, respectively. For the nine months ended September 30, 2014 and 2013, general and administrative expenses were $18.1 million and $18.6 million, respectively. General and administrative expenses include such costs as salaries, corporate overhead, professional fees, among other items.

Acquisition-Related Expenses

For the three months ended September 30, 2014 and 2013, acquisition-related expenses were $2.8 million and $1.4 million, respectively. For the nine months ended September 30, 2014 and 2013, acquisition-related expenses were $8.6 million and $3.1 million, respectively. The increase in acquisition-related expenses is primarily due to increased acquisition activity during 2014.

Depreciation and Amortization Expense

For the three months ended September 30, 2014 and 2013, depreciation and amortization expense was $35.8 million and $29.6 million, respectively. For the nine months ended September 30, 2014 and 2013, depreciation and amortization expense was $104.3 million and $87.7 million, respectively. The increase in depreciation and amortization expense for the three and nine months ended September 30, 2014, as compared to the same periods in 2013, is primarily due to the increase in the size of our portfolio.

Listing Expenses

For the nine months ended September 30, 2013, listing expenses were $4.4 million. We did not incur any listing expenses subsequent to March 31, 2013.

Interest Expense and Net Change in the Fair Value of Derivative Financial Instruments

Total interest expense, which includes the net change in the fair value of derivative financial instruments, decreased by $2.2 million during the three months ended September 30, 2014, as compared to the same period in 2013. The decrease was primarily due to the net change in the fair value of financial instruments. During the three months ended September 30, 2014, the fair market value of our derivatives increased $2.6 million, as compared to a net decrease of $2.0 million during the three months ended September 30, 2013. The increase in the fair value during the three months ended September 30, 2014 was primarily due to an increase in the yield curve, which positively impacted the fair market value of our longer term derivatives as compared to a decrease in the yield curve during the same period in 2013.

Total interest expense, which includes the net change in the fair value of derivative financial instruments increased by $12.2 million during the nine months ended September 30, 2014, as compared to the same period in 2013. The increase was primarily due to the net change in the fair value of financial instruments. During the nine months ended September 30, 2014, the fair market value of our derivatives decreased $0.9 million, as compared to a net increase of $8.6 million during the nine months ended September 30, 2013.

To achieve our objectives, we borrow at fixed rates and variable rates. We also enter into derivative financial instruments, such as interest rate swaps, in order to mitigate our interest rate risk on a related financial instrument. We do not enter into derivative or interest rate transactions for speculative purposes. Derivatives not designated as hedges are not speculative and are used to manage our exposure to interest rate movements.

Gain on Sales of Real Estate

For the three and nine months ended September 30, 2014, we realized gains of $11.8 million from the disposition of two portfolios of medical office buildings. We did not sell any properties during the three and nine months ended September 30, 2013.

30

Non-GAAP Financial Measures

FFO and Normalized FFO

We compute FFO in accordance with the current standards established by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO, as net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP), excluding gains or losses from sales of property and impairment write-downs of depreciable assets, plus depreciation and amortization, and after adjustments for unconsolidated partnerships and joint ventures. We present this non-GAAP financial measure because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs. Historical cost accounting assumes that the value of real estate assets diminishes ratably over time. Since real asset values have historically risen or fallen based on market conditions, many industry investors have considered the presentation of operating results for real estate companies that use historical cost accounting to be insufficient by themselves. Because FFO excludes depreciation and amortization unique to real estate, among other items, it provides a perspective not immediately apparent from net income or loss attributable to common stockholders/unitholders.

Our methodology for calculating FFO may be different from methods utilized by other REITs and, accordingly, may not be comparable to such other REITs. FFO should not be considered as an alternative to net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of sufficient cash flow to fund all of our needs. FFO should be reviewed in connection with other GAAP measurements.

We also compute Normalized FFO, which excludes from FFO (i) acquisition-related expenses, (ii) listing expenses, (iii) net gain or loss on change in the fair value of derivative financial instruments, (iv) gain or loss on extinguishment of debt, (v) noncontrolling income or loss from partnership units included in diluted shares (only applicable to HTA) and (vi) other normalizing items. We present this non-GAAP financial measure because it allows for the comparison of our operating performance to other REITs and between periods on a consistent basis. Our methodology for calculating Normalized FFO may be different from the methods utilized by other REITs and, accordingly, may not be comparable to other REITs. Normalized FFO should not be considered as an alternative to net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of sufficient cash flow to fund our needs. Normalized FFO should be reviewed in connection with other GAAP measurements.

The amounts included in the calculation of FFO and Normalized FFO are generally the same for HTALP and HTA, except for net income or loss attributable to common stockholders/unitholders, noncontrolling income or loss from partnership units included in diluted shares (only applicable to HTA) and the weighted average number of shares or units outstanding.

31

The following is the reconciliation of HTA’s FFO and Normalized FFO to net income attributable to common stockholders for the three and nine months ended September 30, 2014 and 2013 (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Net income attributable to common stockholders	$	16,032		$	4,823		$	24,179		$	20,199
Depreciation and amortization expense	35,802			29,581			104,346			87,725
Gain on sales of real estate	(11,766		)	—			(11,766		)	—
FFO	$	40,068		$	34,404		$	116,759		$	107,924
Acquisition-related expenses	2,802			1,403			8,647			3,086
Listing expenses	—			—			—			4,405
Net (gain) loss on change in fair value of derivative financial instruments	(2,564		)	1,955			857			(8,573		)
Loss on extinguishment of debt, net	5,028			—			4,663			—
Noncontrolling income from partnership units included in diluted shares	160			173			252			384
Other normalizing items	—			(4		)	209			554
Normalized FFO	$	45,494		$	37,931		$	131,387		$	107,780
Net income attributable to common stockholders per diluted share	$	0.07		$	0.02		$	0.10		$	0.09
FFO adjustments per diluted share, net	0.10			0.13			0.39			0.39
FFO per diluted share	$	0.17		$	0.15		$	0.49		$	0.48
Normalized FFO adjustments per diluted share, net	0.02			0.01			0.06			0.00
Normalized FFO per diluted share	$	0.19		$	0.16		$	0.55		$	0.48
Weighted average number of diluted common shares outstanding	241,432			235,023			240,608			226,771

The following is the reconciliation of HTALP’s FFO and Normalized FFO to net income attributable to common unitholders for the three and nine months ended September 30, 2014 and 2013 (in thousands, except per unit data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Net income attributable to common unitholders	$	16,192		$	4,996		$	24,431		$	20,583
Depreciation and amortization expense	35,802			29,581			104,346			87,725
Gain on sales of real estate	(11,766		)	—			(11,766		)	—
FFO	$	40,228		$	34,577		$	117,011		$	108,308
Acquisition-related expenses	2,802			1,403			8,647			3,086
Listing expenses	—			—			—			4,405
Net (gain) loss on change in fair value of derivative financial instruments	(2,564		)	1,955			857			(8,573		)
Loss on extinguishment of debt, net	5,028			—			4,663			—
Other normalizing items	—			(4		)	209			554
Normalized FFO	$	45,494		$	37,931		$	131,387		$	107,780
Net income attributable to common unitholders per diluted unit	$	0.07		$	0.02		$	0.10		$	0.09
FFO adjustments per diluted unit, net	0.10			0.13			0.39			0.38
FFO per diluted unit	$	0.17		$	0.15		$	0.49		$	0.47
Normalized FFO adjustments per diluted unit, net	0.02			0.01			0.05			0.00
Normalized FFO per diluted unit	$	0.19		$	0.16		$	0.54		$	0.47
Weighted average number of diluted common units outstanding	241,948			235,570			241,124			228,188

32

NOI, Cash NOI and Same-Property Cash NOI

NOI is a non-GAAP financial measure that is defined as net income or loss (computed in accordance with GAAP) before (i) general and administrative expenses, (ii) acquisition-related expenses, (iii) depreciation and amortization expense, (iv) listing expenses, (v) interest expense and net change in the fair value of derivative financial instruments, (vi) gain or loss on sales of real estate, (vii) gain or loss on extinguishment of debt and (viii) other income or expense. We believe that NOI provides an accurate measure of the operating performance of our operating assets because NOI excludes certain items that are not associated with the management of our properties. Additionally, we believe that NOI is a widely accepted measure of comparative operating performance of REITs. However, our use of the term NOI may not be comparable to that of other REITs as they may have different methodologies for computing this amount. NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. NOI should be reviewed in connection with other GAAP measurements.

Cash NOI is a non-GAAP financial measure which excludes from NOI (i) straight-line rent adjustments, (ii) amortization of below and above market leases and (iii) lease termination fees. We believe that Cash NOI provides another measurement of the operating performance of our operating assets. Additionally, we believe that Cash NOI is a widely accepted measure of comparative operating performance of REITs. However, our use of the term Cash NOI may not be comparable to that of other REITs as they may have different methodologies for computing this amount. Cash NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. Cash NOI should be reviewed in connection with other GAAP measurements.

To facilitate the comparison of Cash NOI between periods, we calculate comparable amounts for a subset of our owned properties referred to as “Same-Property.” Same-Property Cash NOI excludes properties which have not been owned and operated during the entire span of all periods presented or are intended to be sold in the near term, notes receivable interest income, and certain non-routine items. Same-Property Cash NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. Same-Property Cash NOI should be reviewed in connection with other GAAP measurements.

The following is the reconciliation of HTA’s and HTALP’s NOI, Cash NOI and Same-Property Cash NOI to net income for the three and nine months ended September 30, 2014 and 2013 (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Net income	$	16,220		$	5,005		$	24,537		$	20,622
General and administrative expenses	5,935			5,980			18,137			18,645
Acquisition-related expenses	2,802			1,403			8,647			3,086
Depreciation and amortization expense	35,802			29,581			104,346			87,725
Listing expenses	—			—			—			4,405
Interest expense and the net change in fair value of derivative financial instruments	12,988			15,188			42,807			30,579
Gain on sales of real estate	(11,766		)	—			(11,766		)	—
Loss on extinguishment of debt, net	5,028			—			4,663			—
Other income	(1		)	(10		)	(41		)	(28		)
NOI	$	67,008		$	57,147		$	191,330		$	165,034
Straight-line rent adjustments, net	(2,526		)	(1,565		)	(6,179		)	(4,934		)
Amortization of below and above market leases, net	617			506			1,892			1,576
Lease termination fees	(26		)	(4		)	(39		)	(36		)
Cash NOI	$	65,073		$	56,084		$	187,004		$	161,640
Notes receivable interest income	(187		)	(562		)	(1,532		)	(1,654		)
Non Same-Property Cash NOI	(10,842		)	(3,088		)	(30,603		)	(9,635		)
Same-Property Cash NOI (1)	$	54,044		$	52,434		$	154,869		$	150,351
(1) Same-Property includes 253 and 250 buildings for the three and nine months ended September 30, 2014 and 2013, respectively.

33

Liquidity and Capital Resources

Our primary sources of cash include (i) cash flow from operations, (ii) borrowings under our unsecured revolving credit facility and (iii) proceeds from the issuances of debt and equity securities. During the next 12 months our primary uses of cash are expected to include (i) acquisitions of medical office buildings and other facilities that serve the healthcare industry, (ii) capital expenditures, (iii) the payment of operating expenses, (iv) debt service payments including principal payments and (v) paying dividends to our stockholders. We anticipate cash flow from operations, restricted cash and reserve accounts and our revolving credit facility, if needed, will be sufficient to fund our operating expenses, capital expenditures and dividends to stockholders. Acquisitions and maturing indebtedness may require funds from the issuance of debt and/or equity securities.

As of September 30, 2014, we had liquidity of $627.9 million, including $609.5 million available on our unsecured revolving credit facility (includes the impact of $5.5 million of outstanding letters of credit) and $18.4 million of cash and cash equivalents. Additionally, as of September 30, 2014, $281.7 million was available for issuance under our ATM program and we had unencumbered properties with a gross book value of approximately $2.4 billion. The unencumbered properties may be used as collateral to secure additional financings in future periods or refinance our current debt as it becomes due. Our ability to raise funds from future debt and equity issuances is dependent on our investment grade credit ratings, general economic and market conditions and our operating performance. In May 2014, Standard & Poor’s upgraded HTA’s investment grade credit rating with a stable outlook.

When we acquire a property, we prepare a capital plan that contemplates the estimated capital needs of that investment. In addition to operating expenses, capital needs may also include costs of refurbishment, tenant improvements or other major capital expenditures. The capital plan for each investment will be adjusted through ongoing, regular reviews of our portfolio or as necessary to respond to unanticipated additional capital needs. As of September 30, 2014, we estimate that our expenditures for capital improvements for the remainder of 2014 will range from approximately $4 million to $6 million depending on leasing activity. As of September 30, 2014, we had $10.3 million of restricted cash and reserve accounts for such capital expenditures. We cannot provide assurance, however, that we will not exceed these estimated expenditure levels.

If we experience lower occupancy levels, reduced rental rates, reduced revenues as a result of asset sales, or increased capital expenditures and leasing costs compared to historical levels due to competitive market conditions for new and renewal leases, the effect would be a reduction of net cash provided by operating activities. If such a reduction of net cash provided by operating activities is realized, we may have a cash flow deficit in subsequent periods. Our estimate of net cash available is based on various assumptions which are difficult to predict, including the levels of our leasing activity and related leasing costs. Any changes in these assumptions could impact our financial results and our ability to fund working capital and unanticipated cash needs.

Cash Flows

The following is a summary of our cash flows for the nine months ended September 30, 2014 and 2013 (in thousands):

	Nine Months Ended September 30,
	2014			2013			Change
Cash and cash equivalents - beginning of period	$	18,081		$	15,956		$	2,125
Net cash provided by operating activities	129,550			118,675			10,875
Net cash used in investing activities	(222,981		)	(251,291		)	28,310
Net cash provided by financing activities	93,765			198,841			(105,076		)
Cash and cash equivalents - end of period	$	18,415		$	82,181		$	(63,766	)

Net cash provided by operating activities increased in 2014 primarily due to $473.5 million of acquisitions since September 30, 2013 partially offset by increased acquisition costs in 2014. We anticipate cash flows from operating activities to increase as a result of contractual rent increases and continued leasing activity in our existing portfolio and as we continue to acquire more properties.

For the nine months ended September 30, 2014, net cash used in investing activities primarily related to the acquisition of real estate operating properties of $229.6 million (excludes assumption of secured mortgage debt) and capital expenditures of $24.2 million, partially offset by proceeds from the sale of real estate of $40.1 million and proceeds from the collection of real estate notes receivable of $20.0 million. For the nine months ended September 30, 2013, net cash used in investing activities primarily related to the acquisition of real estate operating properties of $223.8 million and capital expenditures of $16.5 million. We anticipate cash flows used in investing activities to increase as we continue to acquire more properties.

34

For the nine months ended September 30, 2014, net cash provided by financing activities primarily related to net proceeds from the issuance of unsecured senior notes of $297.6 million, partially offset by dividends to holders of our common stock of $102.5 million, payments on our mortgage loans of $90.4 million and net payments on our unsecured revolving credit facility of $20.0 million. For the nine months ended September 30, 2013, net cash provided by financing activities primarily related to net proceeds from the issuance of unsecured senior notes of $297.6 million and the net proceeds of shares of common stock issued through our prior ATM program of $229.5 million, partially offset by payments on our secured real estate term loan and mortgage loans of $155.3 million, net payments on our unsecured revolving credit facility of $72.0 million and dividends to holders of our common stock of $95.6 million.

Dividends

The amount of dividends HTA pays to its stockholders is determined by its Board of Directors, in its sole discretion, and is dependent on a number of factors, including funds available, our financial condition, capital expenditure requirements, and annual dividend distribution requirements needed to maintain our status as a REIT under the Internal Revenue Code of 1986, as amended. HTA has paid dividends monthly or quarterly since February 2007 and if our investments produce sufficient cash flow, we expect to continue to pay dividends to our stockholders. Because our cash available for dividend distributions in any year may be less than 90% of our taxable income for the year, we may obtain the necessary funds through borrowings, issuing new securities or selling assets to pay out enough of our taxable income to satisfy our dividend distribution requirement. HTA’s organizational documents do not establish a limit on dividends that may constitute a return of capital for federal income tax purposes. The dividend HTA pays to its stockholders is equal to the distributions received from HTALP in accordance with the terms of HTALP’s partnership agreement. In July 2014, HTA’s Board of Directors determined that it was in the best interest of its stockholders to increase the quarterly dividends to an annualized rate of $0.58 per share. It is HTA’s intention to continue to pay dividends. However, HTA’s Board of Directors may reduce our dividend rate and HTA cannot guarantee the timing and amount of dividends that it may pay in the future, if any.

For the nine months ended September 30, 2014, HTA paid cash dividends of $102.5 million. In October 2014, HTA paid cash dividends of $34.7 million for the quarter ended September 30, 2014. On October 28, 2014, HTA’s Board of Directors authorized a quarterly cash dividend of $0.145 per share to be paid on January 6, 2015 to stockholders of record on December 29, 2014.

Financing

We have historically maintained a low leveraged balance sheet and intend to continue to maintain this structure over the long run. However, our total leverage may fluctuate on a short term basis as we execute our business strategy. As of September 30, 2014, our leverage ratio of debt to total capitalization was 34.8%.

As of September 30, 2014, we had debt outstanding of $1.5 billion and the weighted average interest rate was 3.74% per annum, inclusive of the impact of our interest rate swaps. The following is a summary of our unsecured and secured debt. See Note 8 to our accompanying condensed consolidated financial statements, for a further discussion of our debt.

Unsecured Revolving Credit Facility

As of September 30, 2014, $609.5 million was available on our unsecured revolving credit facility. Our unsecured revolving credit facility matures in March 2016 and includes a one-year extension, at the option of the borrower, subject to certain conditions.

Unsecured Term Loans

As of September 30, 2014, we had $455.0 million of unsecured term loans outstanding, of which $300.0 million matures in January 2018 and $155.0 million matures in July 2019. Our $300.0 million term loan includes a one-year extension, at the option of the borrower, subject to certain conditions.

Unsecured Senior Notes

In June 2014, we issued $300.0 million of unsecured senior notes that mature in July 2021. In addition, we have $300.0 million of unsecured senior notes that mature in April 2023.

Mortgage Loans

During the nine months ended September 30, 2014, we made payments of $90.4 million on our mortgage loans and we have $2.1 million of principal payments due during the remainder of 2014. During the nine months ended September 30, 2014, we assumed mortgage loans with a fair value of $91.5 million as part of our acquisitions.

Commitments and Contingencies

See Note 10 to our accompanying condensed consolidated financial statements for a further discussion of our commitments and contingencies.

35

Debt Service Requirements

We are required by the terms of our applicable loan documents to meet certain financial covenants, such as minimum net worth and liquidity, and reporting requirements, among others. As of September 30, 2014, we believe that we were in compliance with all such covenants and we are not aware of any covenants that it is reasonably likely that we would not be able to meet.

Off-Balance Sheet Arrangements

As of and during the nine months ended September 30, 2014, we had no off-balance sheet arrangements.

Inflation

We are exposed to inflation risk as income from future long-term leases is the primary source of our cash flows from operations. There are provisions in the majority of our tenant leases that protect us from the impact of normal inflation. These provisions include rent escalations, reimbursement billings for operating expense pass-through charges, and real estate tax and insurance reimbursements on a per square foot allowance. However, due to the long-term nature of our leases, among other factors, the leases may not re-set frequently enough to cover inflation.

Federal Income Tax Changes and Updates for Incorporation in Existing Registration Statements

The following discussion updates the disclosures under “Material U.S. Federal Income Tax Considerations” in the prospectus dated December 21, 2012 contained in our Registration Statement on Form S-3 filed with the SEC on December 21, 2012 and in our other registration statements into which this Quarterly Report on Form 10-Q is incorporated by reference.

The second paragraph of the section captioned “Investments in Certain Debt Instruments” is replaced in its entirety with the following:

“If the outstanding principal balance of a mortgage loan exceeds the fair market value of the real property securing the loan at the time we commit to acquire the loan, or agree to modify the loan in a manner that is treated as an acquisition of a new loan for U.S. federal income tax purposes (such fair market value is referred to as the “loan value” of the real property), then a portion of such loan may not be a qualifying real estate asset. Under current law it is not clear how to determine what portion of such a loan will be treated as a qualifying real estate asset. The IRS has stated that it will not challenge a REITs treatment of a loan as being in part a real estate asset if the REIT treats the loan as being a real estate asset in an amount that is equal to the lesser of the fair market value of the loan and the greater of the current value of the real property securing the loan, or the loan value of the real property securing the loan.”

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There were no material changes in the information regarding market risk that was provided in our 2013 Annual Report on Form 10-K. The table below presents, as of September 30, 2014, the principal amounts of our fixed and variable debt and the weighted average interest rates excluding the impact of interest rate swaps by year of expected maturity to evaluate the expected cash flows and sensitivity to interest rate changes (in thousands, except interest rates):

	Expected Maturity Date
	2014			2015			2016			2017			2018			Thereafter			Total
Fixed rate debt	$	1,958		$	72,908		$	69,036		$	102,110		$	14,197		$	718,987		$	979,196
Weighted average interest rate on fixed rate debt (per annum)	4.48		%	5.25		%	5.33		%	5.78		%	5.39		%	4.15		%	4.34		%
Variable rate debt	$	147		$	546		$	35,589		$	634		$	300,684		$	181,990		$	519,590
Weighted average interest rate on variable rate debt based on forward rates in effect as of September 30, 2014 (per annum)	1.60		%	2.35		%	3.33		%	3.99		%	4.02		%	4.90		%	2.60		%

Our total debt was $1.5 billion as of September 30, 2014. We had fixed and variable rate debt with interest rates ranging from 1.35% to 12.75% per annum and a weighted average interest rate of 3.36% per annum as of September 30, 2014, excluding the impact of interest rate swaps. We had $979.2 million (excluding net premium/discount) of fixed rate debt, or 65% of total debt, at a weighted average interest rate of 4.34% per annum, and $519.6 million (excluding net premium/discount) of variable rate debt, or 35% of total debt, at a weighted average interest rate of 1.52% per annum as of September 30, 2014, excluding the impact of interest rate swaps.

36

As of September 30, 2014, the fair value of our fixed rate debt was $990.2 million and the fair value of our variable rate debt was $519.6 million based upon prevailing market rates as of September 30, 2014.

As of September 30, 2014, we had interest rate swaps outstanding that effectively fix $482.1 million of our variable rate debt. Including the impact of these interest rate swaps, the effective rate on our variable rate and total debt is 2.60% and 3.74% per annum, respectively.

In addition to changes in interest rates, the value of our future properties is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants, which may affect our ability to refinance our debt if necessary.

Item 4. Controls and Procedures

Healthcare Trust of America, Inc.

HTA’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to HTA’s management, including HTA’s Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer, principal financial officer and principal accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

As of September 30, 2014, an evaluation was conducted by HTA under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that HTA’s disclosure controls and procedures were effective.

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2014 that have materially affected, or are reasonably believed to be likely to materially affect, HTA’s internal control over financial reporting.

Healthcare Trust of America Holdings, LP

HTALP’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to HTALP’s management, including HTA’s Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer, principal financial officer and principal accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

As of September 30, 2014, an evaluation was conducted by HTALP under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, HTA’s Chief Executive Officer and the Chief Financial Officer, on behalf of HTA in its capacity as general partner of HTALP, concluded that HTALP’s disclosure controls and procedures were effective.

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2014 that have materially affected, or are reasonably believed to be likely to materially affect, HTALP’s internal control over financial reporting.

37

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are subject to claims and litigation arising in the ordinary course of business. We do not believe any liability from any reasonably foreseeable disposition of such claims and litigation, individually or in the aggregate, would have a material adverse effect on our accompanying condensed consolidated financial statements.

Item 1A. Risk Factors

There are no material changes from the risk factors previously disclosed in our 2013 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

During the three months ended September 30, 2014, we made no repurchase of shares of HTA’s common stock or HTALP’s common units.

Item 6. Exhibits

The exhibits listed on the Exhibit Index (following the signatures section of this Quarterly Report on Form 10-Q) are included, and incorporated by reference, in this Quarterly Report on Form 10-Q.

38

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned thereunto duly authorized.

	Healthcare Trust of America, Inc.
By:	/s/ Scott D. Peters	Chief Executive Officer, President and Chairman
	Scott D. Peters	(Principal Executive Officer)
Date:	October 29, 2014
By:	/s/ Robert A. Milligan	Chief Financial Officer
	Robert A. Milligan	(Principal Financial Officer and Principal Accounting Officer)
Date:	October 29, 2014

	Healthcare Trust of America Holdings, LP
By:	Healthcare Trust of America, Inc.,
	its General Partner
By:	/s/ Scott D. Peters	Chief Executive Officer, President and Chairman
	Scott D. Peters	(Principal Executive Officer)
Date:	October 29, 2014
By:	/s/ Robert A. Milligan	Chief Financial Officer
	Robert A. Milligan	(Principal Financial Officer and Principal Accounting Officer)
Date:	October 29, 2014

39

EXHIBIT INDEX

Following the consummation of the merger of NNN Realty Advisors, Inc., which previously served as our sponsor, with and into a wholly owned subsidiary of Grubb & Ellis Company on December 7, 2007, NNN Healthcare/Office REIT, Inc., NNN Healthcare/Office REIT Holdings, L.P., NNN Healthcare/Office REIT Advisor, LLC and NNN Healthcare/Office Management, LLC changed their names to Grubb & Ellis Healthcare REIT, Inc., Grubb & Ellis Healthcare REIT Holdings, LP, Grubb & Ellis Healthcare REIT Advisor, LLC, and Grubb & Ellis Healthcare Management, LLC, respectively.

Following the Registrant’s transition to self-management, on August 24, 2009, Grubb & Ellis Healthcare REIT, Inc. and Grubb & Ellis Healthcare REIT Holdings, LP changed their names to Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP, respectively.

The following Exhibit Index refers to the entity names used prior to such name changes in order to accurately reflect the names of the parties on the documents listed.

Pursuant to Item 601(a)(2) of Regulation S-K, this Exhibit Index immediately precedes the exhibits.

The following exhibits are included, or incorporated by reference, in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (and are numbered in accordance with Item 601 of Regulation S-K).

10.1	Amended and Restated Employment Agreement between Healthcare Trust of America, Inc. and Robert A. Milligan dated August 22, 2014 (included as Exhibit 10.1 to our Current Report on Form 8-K filed August 22, 2014 and incorporated herein by reference).
31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.2*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.3*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
31.4*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.1**	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
32.2**	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
32.3**	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.4**	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document
*	Filed herewith.
**	Furnished herewith.

40

EX-31.1

Exhibit 31.1

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Scott D. Peters, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman

Date: October 29, 2014

EX-31.2

Exhibit 31.2

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Robert A. Milligan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer

Date: October 29, 2014

EX-31.3

Exhibit 31.3

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Scott D. Peters, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: October 29, 2014

EX-31.4

Exhibit 31.4

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Robert A. Milligan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: October 29, 2014

EX-32.1

Exhibit 32.1

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc., or the Company, for the period ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Scott D. Peters, Chief Executive Officer, President and Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman

Date: October 29, 2014

EX-32.2

Exhibit 32.2

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc., or the Company, for the period ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Robert A. Milligan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer

Date: October 29, 2014

EX-32.3

Exhibit 32.3

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP, or the Company, for the period ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Scott D. Peters, Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Scott D. Peters
	Scott D. Peters
	Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: October 29, 2014

EX-32.4

Exhibit 32.4

CERTIFICATION

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP, or the Company, for the period ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Robert A. Milligan, Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Robert A. Milligan
	Robert A. Milligan
	Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

Date: October 29, 2014

XML

Intangibles Assets and Liabilities (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Assets
Gross	$ 471,362	$ 476,296
Accumulated amortization	(172,708)	(151,860)
Total	298,654	324,436
Weighted average remaining amortization period in years	15 years 4 months 24 days	15 years 10 months 24 days
Liabilities
Gross	17,826	17,816
Accumulated amortization	(6,306)	(6,019)
Total	11,520	11,797
Weighted average remaining amortization period in years	18 years 1 month 6 days	18 years 4 months 24 days
Below Market Leases
Liabilities
Gross	13,999	13,989
Weighted average remaining amortization period in years	12 years 1 month 6 days	12 years 4 months 24 days
Above Market Leasehold Interests
Liabilities
Gross	3,827	3,827
Weighted average remaining amortization period in years	32 years 4 months 24 days	33 years 1 month 6 days
In Place Leases
Assets
Gross	225,023	213,338
Weighted average remaining amortization period in years	8 years 7 months 6 days	8 years 9 months 18 days
Tenant Relationships
Assets
Gross	188,380	198,519
Weighted average remaining amortization period in years	10 years 4 months 24 days	10 years 6 months
Above Market Leases
Assets
Gross	26,566	26,799
Weighted average remaining amortization period in years	5 years 9 months 18 days	6 years 3 months 18 days
Below Market Leasehold Interests
Assets
Gross	$ 31,393	$ 37,640
Weighted average remaining amortization period in years	67 years 8 months 12 days	68 years 10 months 24 days

XML

Supplemental Cash Flow Information (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Supplemental Disclosure of Cash Flow Information:
Interest paid	$ 29,758	$ 27,743
Income taxes paid	757	904
The following represents the significant increase (decrease) in certain assets and liabilities in connection with our acquisitions:
Debt and interest rate swaps	88,845	17,982
Financing Activities:
Dividend distributions declared, but not paid	$ 34,652	$ 34,238

XML

Stockholders' Equity and Partners' Capital (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended			3 Months Ended	9 Months Ended		0 Months Ended	9 Months Ended	0 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 Restricted Common Stock	Sep. 30, 2014 Restricted Common Stock	Sep. 30, 2013 Restricted Common Stock	Sep. 30, 2013 Listing Expenses Restricted Common Stock	Sep. 30, 2013 General and Administrative Expense Restricted Common Stock	Sep. 30, 2013 General and Administrative Expense Restricted Common Stock	Sep. 30, 2014 2006 Incentive Plan	Oct. 28, 2014 Subsequent Event	Sep. 30, 2014 Common Stock Offering	Feb. 28, 2014 Common Stock Offering Maximum	Sep. 30, 2014 LTIP	Sep. 30, 2013 LTIP Listing Expenses	Sep. 30, 2013 LTIP Listing Expenses
Common Stock Offerings
Maximum amount of common stock authorized														$ 300,000,000
Issuance of common stock (in shares)													1,541,715
Stock issued, average price per share (in usd per share)													$ 11.86
Remaining available amount of common stock for issuance													281,700,000
Common Stock Dividends
Dividends declared per common share (in usd per share)	$ 0.15	$ 0.14	$ 0.43	$ 0.43								$ 0.145
Incentive Plan
Number of shares authorized											10,000,000
Number of shares available for grant											4,594,200
Allocated share-based compensation expense					1,000,000	3,300,000	2,000,000	600,000	500,000	1,400,000						0	3,100,000
Nonvested awards, total compensation cost not yet recognized					$ 5,200,000	$ 5,200,000									$ 4,500,000
Contingent units															450,000
Period for recognition						2 years

XML

Derivative Financial Instruments - Derivative Instruments Fair Value Table (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Derivatives, Fair Value
Derivative financial instruments, asset	$ 3,290	$ 5,073
Derivative financial instruments, liability	4,127	5,053
Interest Rate Swap | Not Designated as Hedging Instrument | Receivables and Other Assets
Derivatives, Fair Value
Derivative financial instruments, asset	3,290	5,073
Interest Rate Swap | Not Designated as Hedging Instrument | Derivative Financial Instruments
Derivatives, Fair Value
Derivative financial instruments, liability	$ 4,127	$ 5,053

XML

Supplemental Cash Flow Information (Tables)

9 Months Ended

Sep. 30, 2014

Supplemental Cash Flow Elements [Abstract]

Schedule of Cash Flow, Supplemental Disclosures

The following is the supplemental cash flow information for the nine months ended September 30, 2014 and 2013 (in thousands):

	Nine Months Ended September 30,
	2014		2013
Interest paid	$	29,758	$	27,743
Income taxes paid	757		904
Supplemental Disclosure of Noncash Activities:
The following represents the significant increase (decrease) in certain assets and liabilities in connection with our acquisitions:
Debt and interest rate swaps	$	88,845	$	17,982
Financing Activities:
Dividend distributions declared, but not paid	$	34,652	$	34,238

XML

Intangibles Assets and Liabilities (Tables)

9 Months Ended

Sep. 30, 2014

Identified Intangibles, Net [Abstract]

Schedule of Identified Intangible Assets and Liabilities, Net

Intangible assets and liabilities consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands, except weighted average remaining amortization period):

	September 30, 2014				December 31, 2013
	Balance			Weighted Average Remaining Amortization Period in Years	Balance			Weighted Average Remaining Amortization Period in Years	Balance Sheet Classification
Assets:
In place leases	$	225,023		8.6	$	213,338		8.8	Lease intangibles
Tenant relationships	188,380			10.4	198,519			10.5	Lease intangibles
Above market leases	26,566			5.8	26,799			6.3	Other intangibles, net
Below market leasehold interests	31,393			67.7	37,640			68.9	Other intangibles, net
	471,362				476,296
Accumulated amortization	(172,708		)		(151,860		)
Total	$	298,654		15.4	$	324,436		15.9
Liabilities:
Below market leases	$	13,999		12.1	$	13,989		12.4	Intangible liabilities, net
Above market leasehold interests	3,827			32.4	3,827			33.1	Intangible liabilities, net
	17,826				17,816
Accumulated amortization	(6,306		)		(6,019		)
Total	$	11,520		18.1	$	11,797		18.4

Summary of Intangible Asset and Liabilities Amortization

The following is a summary of the net intangible amortization for the three and nine months ended September 30, 2014 and 2013 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Amortization recorded against rental income related to above or below market leases	$	505	$	417	$	1,534	$	1,298
Rental expense related to above or below market leasehold interests	112		89		358		278
Amortization expense related to in place leases and tenant relationships	12,066		9,955		36,247		29,970

XML

Fair Value of Financial Instruments - Assets and Liabilities at Fair Value (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivative financial instruments, asset	$ 3,290	$ 5,073
Derivative financial instruments, liability	4,127	5,053
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivative financial instruments, asset	3,290	5,073
Derivative financial instruments, liability	4,127	5,053
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1 )
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivative financial instruments, asset	0	0
Derivative financial instruments, liability	0	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivative financial instruments, asset	3,290	5,073
Derivative financial instruments, liability	4,127	5,053
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Derivative financial instruments, asset	0	0
Derivative financial instruments, liability	$ 0	$ 0

XML

Debt - Net (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument
Total debt, gross	$ 1,498,786	$ 1,213,676
Net premium (discount)	(1,650)	565
Total	1,497,136	1,214,241
Unsecured Term Loans
Debt Instrument
Total debt, gross	455,000	455,000
Unsecured Senior Notes
Debt Instrument
Total debt, gross	600,000	300,000
Mortgages | Fixed Rate Mortgages
Debt Instrument
Total debt, gross	379,196	373,751
Mortgages | Variable Rate Mortgages
Debt Instrument
Total debt, gross	29,590	29,925
Unsecured Revolving Credit Facility
Debt Instrument
Line of credit facility, amount outstanding	$ 35,000	$ 55,000

XML

Dispositions and Assets Held for Sale (Details) (USD $)	3 Months Ended			9 Months Ended					1 Months Ended
	Sep. 30, 2014 building	Mar. 31, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013 property	Sep. 30, 2014 Assets Held-for-sale, Real Estate Investments	Sep. 30, 2014 Assets Held-for-sale, Other Intangibles	Oct. 29, 2014 Subsequent Event
Long Lived Assets Held-for-sale [Line Items]
Number of dispositions of portfolios of medical office buildings	2
Aggregate gross sales price of disposed portfolios of medical office buildings	$ 42,000,000
Gain from sale of disposed portfolios of medical office buildings	11,766,000		0	11,766,000	0				16,000,000
Gross proceeds from sale of property	40,900,000
Assets held for sale, net	22,930,000			22,930,000		0	18,900,000	3,100,000
Number of properties held-for-sale						1
Depreciation expense on reclassified assets		$ 800,000

XML

Per Share Data of HTA (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013
Numerator:
Net income	$ 16,220		$ 5,005		$ 24,537		$ 20,622
Net income attributable to noncontrolling interests	(188)	[1]	(182)	[1]	(358)	[1]	(423)	[1]
Net income attributable to common stockholders/unitholders	$ 16,032		$ 4,823		$ 24,179		$ 20,199
Denominator:
Weighted average number of shares/units outstanding — basic	238,968		232,514		238,099		225,132
Dilutive shares	2,464		2,509		2,509		1,639
Weighted average number of shares/units outstanding — diluted	241,432		235,023		240,608		226,771
Earnings per common share - basic
Net income attributable to common stockholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09
Earnings per common share - diluted
Net income attributable to common stockholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09

[1] Includes amounts attributable to redeemable noncontrolling interests.

XML

Derivative Financial Instruments - Derivative Offsetting (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative financial instruments, asset	$ 3,290	$ 5,073
Derivative assets, amounts subject to enforceable master netting arrangements	(1,404)	(2,078)
Derivative assets, net amounts	1,886	2,995
Derivative liabilities	4,127	5,053
Derivative liabilities, amounts subject to enforceable master netting arrangements	(1,404)	(2,078)
Derivative liabilities, net amounts	$ 2,723	$ 2,975

XML

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America (“GAAP”), in all material respects, and have been consistently applied in preparing our accompanying condensed consolidated financial statements.

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2013 Annual Report on Form 10-K.

Variable Interest Entities

As of September 30, 2014, our condensed consolidated financial statements include four VIEs, which we were deemed to be the primary beneficiary. All of the VIEs were established during the third quarter of 2014 to facilitate potential Section 1031 Exchanges. The impact of consolidating the VIEs increased our total real estate assets by $72.2 million, but had no impact on our total assets.

Real Estate Investments

Depreciation expense of buildings and improvements for the three months ended September 30, 2014 and 2013 was $22.6 million and $18.9 million, respectively. Depreciation expense of buildings and improvements for the nine months ended September 30, 2014 and 2013 was $65.0 million and $55.6 million, respectively.

Noncontrolling Interests

HTA’s net income attributable to noncontrolling interests in the accompanying condensed consolidated statements of operations relate to both noncontrolling interest reflected within equity and redeemable noncontrolling interest of limited partners reflected outside of equity in the accompanying condensed consolidated balance sheets. Limited partner units, including LTIP awards, are accounted for as partners’ capital in HTALP’s accompanying condensed consolidated balance sheets and as noncontrolling interest reflected within equity or redeemable noncontrolling interest of limited partners reflected outside of equity in HTA’s accompanying condensed consolidated balance sheets.

Redeemable noncontrolling interests relate to the interests in our consolidated entities that are not wholly owned by us. As these redeemable noncontrolling interests provide for redemption features not solely within our control, we classify such interests outside of permanent equity or partners’ capital.

Recently Issued or Adopted Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Updated (“ASU”) 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360) which changes the requirements for reporting discontinued operations. ASU 2014-08 changes the threshold for disclosing discontinued operations and the related disclosure requirements. Pursuant to ASU 2014-08, only disposals representing a strategic shift, such as a major line of business, a major geographical area or majority equity investment, should be presented as a discontinued operation. If the disposal does qualify as a discontinued operation under ASU 2014-08, the entity will be required to provide expanded disclosures. The guidance will be applied prospectively to new disposals and new classifications of disposal groups held for sale after the effective date. ASU 2014-08 is effective for annual periods beginning on or after December 15, 2014 with early adoption permitted but only for disposals or classifications as held for sale which have not been reported in financial statements previously issued or available for issuance. We adopted ASU 2014-08 as of January 1, 2014 and believe future sales of our individual operating properties will no longer qualify as discontinued operations.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. ASU 2014-09 is effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. We are still evaluating the impact of adopting ASU 2014-09 on our financial statements.

In June 2014, the FASB issued ASU 2014-12, Compensation - Stock Compensation (Topic 718). ASU 2014-12 requires that a performance target requisite service period be treated as a performance condition and, as a result, this type of performance condition may delay expense recognition until achievement of the performance target is probable. ASU 2014-12 is effective for reporting periods beginning after December 15, 2015, and early adoption is permitted. We will adopt ASU 2014-12 effective January 1, 2016 and it is not anticipated to have a material impact on our financial statements.

XML

Debt - Principal Maturity Schedule (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
2014	$ 2,105
2015	73,454
2016	104,625
2017	102,744
2018	314,881
Thereafter	900,977
Total	$ 1,498,786	$ 1,213,676

XML

Stockholders' Equity and Partners' Capital (Tables)

9 Months Ended

Sep. 30, 2014

LTIP

Class of Stock

Schedule of Nonvested Share Activity

The following is a summary of the activity in our LTIP units during 2014:

	LTIP Units		Weighted Average Grant Date Fair Value
Balance as of December 31, 2013	516,500		$	9.43
Granted	—		—
Vested	—		—
Forfeited	(6,020	)	5.62
Balance as of September 30, 2014	510,480		$	9.47

Restricted Stock

Class of Stock

Schedule of Nonvested Share Activity

The following is a summary of the activity in our restricted common stock during 2014:

	Restricted Common Stock		Weighted Average Grant Date Fair Value
Balance as of December 31, 2013	641,000		$	10.34
Granted	563,200		10.21
Vested	(148,000	)	10.07
Forfeited	(55,600	)	9.96
Balance as of September 30, 2014	1,000,600		$	10.46

XML

Derivative Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

The following table lists the derivative financial instrument assets and (liabilities) held by us as of September 30, 2014 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	200,000	LIBOR	1.23	%	$	(1,404	)	Swap	3/29/2017
100,000		LIBOR	0.86		(465		)	Swap	6/15/2016
50,000		LIBOR	1.39		812			Swap	7/17/2019
105,000		LIBOR	1.24		2,478			Swap	7/17/2019
27,062		LIBOR	4.98		(2,258		)	Swap	5/1/2020

The following table lists the derivative financial instrument assets and (liabilities) held by us as of December 31, 2013 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	200,000	LIBOR	1.23	%	$	(2,078	)	Swap	3/29/2017
100,000		LIBOR	0.86		(729		)	Swap	6/15/2016
50,000		LIBOR	1.39		1,350			Swap	7/17/2019
105,000		LIBOR	1.24		3,723			Swap	7/17/2019
27,618		LIBOR	4.98		(2,246		)	Swap	5/1/2020

Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location

As of September 30, 2014 and December 31, 2013, the gross fair value of our derivative financial instruments was as follows (in thousands):

	Asset Derivatives					Liability Derivatives
		Fair Value					Fair Value
Derivatives Not Designated as Hedging Instruments:	Balance Sheet Location	September 30, 2014		December 31, 2013		Balance Sheet Location	September 30, 2014		December 31, 2013
Interest rate swaps	Receivables and other assets	$	3,290	$	5,073	Derivative financial instruments	$	4,127	$	5,053

There were no derivatives offset in our accompanying condensed consolidated balance sheets as of September 30, 2014 and December 31, 2013. As of September 30, 2014 and December 31, 2013, we had derivatives subject to enforceable master netting arrangements which allowed for net cash settlement with the respective counterparties (in thousands):

	September 30, 2014							December 31, 2013
	Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts		Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts
Asset derivatives	$	3,290	$	(1,404	)	$	1,886	$	5,073	$	(2,078	)	$	2,995
Liability derivatives	4,127		(1,404		)	2,723		5,053		(2,078		)	2,975

XML

Debt - Textuals (Details) (USD $)	0 Months Ended	9 Months Ended		0 Months Ended		9 Months Ended		0 Months Ended				9 Months Ended		9 Months Ended
	Jan. 07, 2014 Unsecured Term Loans $300.0 Million Unsecured Term Loan	Sep. 30, 2014 Unsecured Term Loans $300.0 Million Unsecured Term Loan	Jan. 07, 2014 Unsecured Term Loans $300.0 Million Unsecured Term Loan	Jan. 07, 2014 Unsecured Term Loans $300.0 Million Unsecured Term Loan Minimum	Jan. 07, 2014 Unsecured Term Loans $300.0 Million Unsecured Term Loan Maximum	Sep. 30, 2014 Unsecured Term Loans $155.0 Million Unsecured Term Loan	Jul. 20, 2012 Unsecured Term Loans $155.0 Million Unsecured Term Loan	Jul. 20, 2012 Unsecured Term Loans $155.0 Million Unsecured Term Loan Minimum	Jul. 20, 2012 Unsecured Term Loans $155.0 Million Unsecured Term Loan Maximum	Mar. 28, 2013 Unsecured Senior Notes Unsecured Senior Notes Due 2023	Jun. 26, 2014 Unsecured Senior Notes Unsecured Senior Notes Due 2021	Sep. 30, 2014 Mortgages	Sep. 30, 2014 Mortgages Variable Rate Mortgages	Sep. 30, 2014 Unsecured Revolving Credit Facility	Sep. 30, 2014 Unsecured Revolving Credit Facility Minimum	Sep. 30, 2014 Unsecured Revolving Credit Facility Maximum
Debt Instrument
Line of credit facility, borrowing capacity														$ 650,000,000
Unsecured credit agreement, extension option period	1 year													1 year
Description of variable rate basis	LIBOR													LIBOR
Basis spread on variable rate		1.20%		1.05%	1.95%	1.70%		1.55%	2.40%					1.30%	1.10%	1.75%
Line of credit facility, commitment fee percentage														0.25%	0.20%	0.50%
Debt instrument, face amount			$ 300,000,000				$ 155,000,000			$ 300,000,000	$ 300,000,000
Weighted average interest rate with interest rate swap impact		2.30%				2.99%							5.56%
Debt instrument, stated interest rate										3.70%	3.375%
Debt instrument, percentage of principal amount received										99.186%	99.205%
Debt instrument, effective interest rate										3.80%	3.50%
Effective percentage rate range, minimum												1.60%
Effective percentage rate range, maximum												12.75%
Weighted average interest rate												5.31%

XML

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The table below presents our assets and liabilities measured at fair value on a recurring basis as of September 30, 2014, aggregated by the applicable Level in the fair value hierarchy (in thousands):

	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1 )		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Derivative financial instruments	$	—	$	3,290	$	—	$	3,290
Liabilities:
Derivative financial instruments	$	—	$	4,127	$	—	$	4,127

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2013, aggregated by the applicable Level in the fair value hierarchy (in thousands):

	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1 )		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Derivative financial instruments	$	—	$	5,073	$	—	$	5,073
Liabilities:
Derivative financial instruments	$	—	$	5,053	$	—	$	5,053

Schedule of Fair Value of Financial Instruments

The following table sets forth the carrying value and fair value of our real estate notes receivable, tenant note receivable and debt (in thousands):

		September 30, 2014				December 31, 2013
	Fair Value Level	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Real estate notes receivable	2	$	8,520	$	8,520	$	28,520	$	28,520
Tenant note receivable	2	3,080		3,028		3,173		3,013
Debt	2	1,497,136		1,509,761		1,214,241		1,237,699

XML

Per Share Data of HTA (Tables)

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA common stock for the three and nine months ended September 30, 2014 and 2013 (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Numerator:
Net income	$	16,220		$	5,005		$	24,537		$	20,622
Net income attributable to noncontrolling interests	(188		)	(182		)	(358		)	(423		)
Net income attributable to common stockholders	$	16,032		$	4,823		$	24,179		$	20,199
Denominator:
Weighted average number of shares outstanding - basic	238,968			232,514			238,099			225,132
Dilutive shares	2,464			2,509			2,509			1,639
Weighted average number of shares outstanding - diluted	241,432			235,023			240,608			226,771
Earnings per common share - basic
Net income attributable to common stockholders	$	0.07		$	0.02		$	0.10		$	0.09
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.07		$	0.02		$	0.10		$	0.09

XML

Organization and Description of Business

9 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of Business

Organization and Description of Business

HTA, a Maryland corporation, and HTALP, a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006. HTA operates as a REIT and is the general partner of HTALP, which is the operating partnership. As of September 30, 2014, HTA owned a 99.0% partnership interest and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the LTIP units) in HTALP. As the sole general partner of HTALP, HTA has the full, exclusive and complete responsibility for HTALP’s day-to-day management and control. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP. As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP, issuing public equity from time to time and guaranteeing certain debts of HTALP. HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity.

HTA is one of the largest publicly-traded REITs focused on medical office buildings in the United States based on gross leasable area (“GLA”). We are primarily focused on acquiring, owning and operating high-quality medical office buildings that are predominantly located on, or aligned with, campuses of nationally or regionally recognized healthcare systems. In addition, we have strong industry relationships, a stable and diversified tenant mix and an extensive and active acquisition network. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we (i) seek internal growth through proactive asset management, leasing and property management oversight, (ii) target mid-sized acquisitions of high-quality medical office buildings in markets with dominant healthcare systems, attractive demographics and that complement our existing portfolio and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage. HTA has qualified to be taxed as a REIT for federal income tax purposes and intends to continue to be taxed as a REIT.

We invest primarily in high-quality medical office buildings in our target markets, and have acquired high-quality medical office buildings and other facilities that serve the healthcare industry with an aggregate purchase price of approximately $3.3 billion through September 30, 2014.

Our principal executive office is located at 16435 North Scottsdale Road, Suite 320, Scottsdale, Arizona, 85254.

XML

Per Unit Data of HTALP (Tables)

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Schedule of Earnings Per Unit, Basic and Diluted

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and nine months ended September 30, 2014 and 2013 (in thousands, except per unit data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Numerator:
Net income	$	16,220		$	5,005		$	24,537		$	20,622
Net income attributable to noncontrolling interests	(28		)	(9		)	(106		)	(39		)
Net income attributable to common unitholders	$	16,192		$	4,996		$	24,431		$	20,583
Denominator:
Weighted average number of units outstanding - basic	241,948			235,570			241,124			228,188
Dilutive units	—			—			—			—
Weighted average number of units outstanding - diluted	241,948			235,570			241,124			228,188
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.07		$	0.02		$	0.10		$	0.09
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.07		$	0.02		$	0.10		$	0.09

XML

Intangibles Assets and Liabilities - Summary of Intangible Amortization (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Amortization recorded against rental income related to above or below market leases
Finite-Lived Intangibles
Amortization of intangible assets and liabilities	$ 505	$ 417	$ 1,534	$ 1,298
Rental expense related to above or below market leasehold interests
Finite-Lived Intangibles
Amortization of intangible assets and liabilities	112	89	358	278
Amortization expense related to in place leases and tenant relationships
Finite-Lived Intangibles
Amortization of intangible assets and liabilities	$ 12,066	$ 9,955	$ 36,247	$ 29,970

XML

Per Unit Data of HTALP (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013
Numerator:
Net income	$ 16,220		$ 5,005		$ 24,537		$ 20,622
Net income attributable to noncontrolling interests	(188)	[1]	(182)	[1]	(358)	[1]	(423)	[1]
Net income attributable to common stockholders/unitholders	16,032		4,823		24,179		20,199
Denominator:
Weighted average number of shares/units outstanding — basic	238,968		232,514		238,099		225,132
Dilutive units	2,464		2,509		2,509		1,639
Weighted average number of shares/units outstanding — diluted	241,432		235,023		240,608		226,771
Earnings per common unit - basic:
Net income attributable to common unitholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09
Earnings per common unit - diluted:
Net income attributable to common unitholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09
Healthcare Trust of America Holdings, LP (HTALP)
Numerator:
Net income	16,220		5,005		24,537		20,622
Net income attributable to noncontrolling interests	(28)	[1]	(9)	[1]	(106)	[1]	(39)	[1]
Net income attributable to common stockholders/unitholders	$ 16,192		$ 4,996		$ 24,431		$ 20,583
Denominator:
Weighted average number of shares/units outstanding — basic	241,948		235,570		241,124		228,188
Dilutive units	0		0		0		0
Weighted average number of shares/units outstanding — diluted	241,948		235,570		241,124		228,188
Earnings per common unit - basic:
Net income attributable to common unitholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09
Earnings per common unit - diluted:
Net income attributable to common unitholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09

[1] Includes amounts attributable to redeemable noncontrolling interests.

XML

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Real estate investments:
Land	$ 272,922	$ 203,001
Building and improvements	2,554,006	2,358,071
Lease intangibles	413,403	411,857
Real estate investments, gross	3,240,331	2,972,929
Accumulated depreciation and amortization	(518,647)	(445,938)
Real estate investments, net (see Note 2)	2,721,684	2,526,991
Assets held for sale, net	22,930	0
Real estate notes receivable	8,520	28,520
Cash and cash equivalents	18,415	18,081
Restricted cash and escrow deposits	31,329	18,114
Receivables and other assets, net	141,561	110,285
Other intangibles, net	42,362	50,343
Total assets	2,986,801	2,752,334
Liabilities:
Debt	1,497,136	1,214,241
Accounts payable and accrued liabilities	98,163	82,893
Derivative financial instruments - interest rate swaps	4,127	5,053
Security deposits, prepaid rent and other liabilities	31,935	35,339
Intangible liabilities, net	11,520	11,797
Total liabilities	1,642,881	1,349,323
Commitments and contingencies
Redeemable noncontrolling interest of limited partners	3,258	3,262
Equity/Partners' Capital:
Preferred stock, $0.01 par value; 200,000,000 shares authorized; none issued and outstanding	0	0
Class A common stock, $0.01 par value; 1,000,000,000 shares authorized; 238,944,761 and 236,880,614 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	2,389	2,369
Additional paid-in capital	2,147,688	2,126,897
Cumulative dividends in excess of earnings	(820,978)	(742,060)
Total stockholders’ equity	1,329,099	1,387,206
Noncontrolling interest	11,563	12,543
Total equity	1,340,662	1,399,749
Total liabilities and equity/partners' capital	2,986,801	2,752,334
Healthcare Trust of America Holdings, LP (HTALP)
Real estate investments:
Land	272,922	203,001
Building and improvements	2,554,006	2,358,071
Lease intangibles	413,403	411,857
Real estate investments, gross	3,240,331	2,972,929
Accumulated depreciation and amortization	(518,647)	(445,938)
Real estate investments, net (see Note 2)	2,721,684	2,526,991
Assets held for sale, net	22,930	0
Real estate notes receivable	8,520	28,520
Cash and cash equivalents	18,415	18,081
Restricted cash and escrow deposits	31,329	18,114
Receivables and other assets, net	141,561	110,285
Other intangibles, net	42,362	50,343
Total assets	2,986,801	2,752,334
Liabilities:
Debt	1,497,136	1,214,241
Accounts payable and accrued liabilities	98,163	82,893
Derivative financial instruments - interest rate swaps	4,127	5,053
Security deposits, prepaid rent and other liabilities	31,935	35,339
Intangible liabilities, net	11,520	11,797
Total liabilities	1,642,881	1,349,323
Commitments and contingencies
Redeemable noncontrolling interest of limited partners	1,765	1,717
Equity/Partners' Capital:
Limited partners’ capital, 2,973,998 and 3,052,918 units issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	12,786	13,818
General partners’ capital, 238,944,761 and 236,880,614 units issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	1,329,369	1,387,476
Total partners’ capital	1,342,155	1,401,294
Total liabilities and equity/partners' capital	$ 2,986,801	$ 2,752,334

XML

Derivative Financial Instruments - Table of Derivative Financial Instruments (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Derivative
Fair value, liability	$ (4,127)	$ (5,053)
Fair value, asset	3,290	5,073
Interest Rate Swap | 1.23%
Derivative
Notional Amount	200,000	200,000
Index	LIBOR	LIBOR
Rate	1.23%	1.23%
Fair value, liability	(1,404)	(2,078)
Interest Rate Swap | 0.86%
Derivative
Notional Amount	100,000	100,000
Index	LIBOR	LIBOR
Rate	0.86%	0.86%
Fair value, liability	(465)	(729)
Interest Rate Swap | 1.39%
Derivative
Notional Amount	50,000	50,000
Index	LIBOR	LIBOR
Rate	1.39%	1.39%
Fair value, asset	812	1,350
Interest Rate Swap | 1.24%
Derivative
Notional Amount	105,000	105,000
Index	LIBOR	LIBOR
Rate	1.24%	1.24%
Fair value, asset	2,478	3,723
Interest Rate Swap | 4.98%
Derivative
Notional Amount	27,062	27,618
Index	LIBOR	LIBOR
Rate	4.98%	4.98%
Fair value, liability	$ (2,258)	$ (2,246)

XML

Condensed Consolidated Statements of Changes In Partners' Capital (USD $) In Thousands, unless otherwise specified	Total	Healthcare Trust of America Holdings, LP (HTALP)	Healthcare Trust of America Holdings, LP (HTALP) General Partner	Healthcare Trust of America Holdings, LP (HTALP) Limited Partner
Balance as of beginning of period at Dec. 31, 2012		$ 1,266,199	$ 1,254,536	$ 11,663
Balance as of beginning of period (in units) at Dec. 31, 2012			214,652	3,056
Increase (Decrease) in Partners' Capital [Roll Forward]
Issuance of general partner units (in units)			20,707
Issuance of general partner units		228,306	228,306
Share-based award transactions, net (in units)			412	(2)
Share-based award transactions, net		5,129	1,952	3,177
Redemptions of general partner units			(28)
Redemptions of general partner units		(287)	(287)
Distributions		(99,651)	(98,630)	(1,021)
Net income attributable to common unitholders	20,199	20,583	20,199	384
Balance as of end of period at Sep. 30, 2013		1,420,279	1,406,076	14,203
Balance as of end of period (in units) at Sep. 30, 2013			235,743	3,054
Balance as of beginning of period at Jun. 30, 2013
Increase (Decrease) in Partners' Capital [Roll Forward]
Net income attributable to common unitholders	4,823	4,996
Balance as of end of period at Sep. 30, 2013		1,420,279
Balance as of beginning of period at Dec. 31, 2013		1,401,294	1,387,476	13,818
Balance as of beginning of period (in units) at Dec. 31, 2013			236,880	3,053
Increase (Decrease) in Partners' Capital [Roll Forward]
Issuance of general partner units (in units)			1,542
Issuance of general partner units		17,742	17,742
Share-based award transactions, net (in units)			508	(6)
Share-based award transactions, net		3,279	3,279
Redemptions of general partner units			(58)
Redemptions of general partner units		(572)	(572)
Redemption of limited partner units (in units)			73	(73)
Redemption of limited partner units		0	362	(362)
Distributions		(104,019)	(103,097)	(922)
Net income attributable to common unitholders	24,179	24,431	24,179	252
Balance as of end of period at Sep. 30, 2014		1,342,155	1,329,369	12,786
Balance as of end of period (in units) at Sep. 30, 2014			238,945	2,974
Balance as of beginning of period at Jun. 30, 2014
Increase (Decrease) in Partners' Capital [Roll Forward]
Net income attributable to common unitholders	16,032	16,192
Balance as of end of period at Sep. 30, 2014		$ 1,342,155

XML

Summary of Significant Accounting Policies (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Accounting Policies [Abstract]
Number of VIEs	4		4
Increase in real estate assets as a result of consolidating the VIEs	$ 72.2		$ 72.2
Building and Improvements
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 22.6	$ 18.9	$ 65.0	$ 55.6

XML

Supplemental Cash Flow Information

9 Months Ended

Sep. 30, 2014

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

Supplemental Cash Flow Information

The following is the supplemental cash flow information for the nine months ended September 30, 2014 and 2013 (in thousands):

	Nine Months Ended September 30,
	2014		2013
Interest paid	$	29,758	$	27,743
Income taxes paid	757		904
Supplemental Disclosure of Noncash Activities:
The following represents the significant increase (decrease) in certain assets and liabilities in connection with our acquisitions:
Debt and interest rate swaps	$	88,845	$	17,982
Financing Activities:
Dividend distributions declared, but not paid	$	34,652	$	34,238

XML

Business Combinations (Details) (USD $)	9 Months Ended		1 Months Ended
	Sep. 30, 2014 acquisition	Sep. 30, 2013	Jun. 30, 2014 Medical Office Buildings in Boston, MA, Miami, FL and Baltimore, MD	Jun. 30, 2014 Medical Office Building in Raleigh, North Carolina	Aug. 31, 2014 Medical Office Buildings in White Plains, New York	Aug. 31, 2014 Medical Office Building in Charleston, South Carolina	Sep. 30, 2014 Medical Office Building in Clearwater, Florida
Business Acquisition [Line Items]
Number of acquisitions	5
Closing costs	$ 5,600,000
Mortgage loans assumed	91,500,000
Business Acquisition, Purchase Price Allocation, Real Estate [Abstract]
Land	70,609,000	13,415,000
Building and improvements	227,458,000	175,039,000
Below market leasehold interests	98,000	1,836,000
Above market leases	1,708,000	1,987,000
In place leases	22,233,000	32,205,000
Tenant relationships		16,541,000
Below market leases	(953,000)	(1,167,000)
Above market debt, net	(2,664,000)	(241,000)
Net assets acquired	318,489,000	239,615,000
Other, net	(939,000)	2,299,000
Aggregate purchase price	$ 317,550,000	$ 241,914,000	$ 200,000,000	$ 11,500,000	$ 64,000,000	$ 24,800,000	$ 17,300,000
Weighted average lives of acquired intangible assets	9 years 1 month 10 days	7 years 4 months 18 days
Weighted average lives of acquired intangible liabilities	8 years 5 months 16 days	5 years 8 months 18 days

XML

Business Combinations (Tables)

9 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Schedule of Purchase Price Allocation

The acquisitions completed during the nine months ended September 30, 2013 were determined to be individually not significant, but material on a collective basis. The allocations for these acquisitions are set forth below in the aggregate (in thousands):

2013 Acquisitions	Total
Land	$	13,415
Building and improvements	175,039
Below market leasehold interests	1,836
Above market leases	1,987
In place leases	32,205
Tenant relationships	16,541
Below market leases	(1,167		)
Above market debt	(241		)
Net assets acquired	239,615
Other, net	2,299
Aggregate purchase price	$	241,914

Since the acquisitions were determined to be individually not significant, but material on a collective basis, the allocations for the 2014 acquisitions are set forth below in the aggregate (in thousands):

2014 Acquisitions	Total
Land	$	70,609
Building and improvements	227,458
Below market leasehold interests	98
Above market leases	1,708
In place leases	22,233
Below market leases	(953		)
Above market debt, net	(2,664		)
Net assets acquired	318,489
Other, net	(939		)
Aggregate purchase price	$	317,550

XML

Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net income	$ 24,537	$ 20,622
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	101,168	86,654
Share-based compensation expense	3,279	5,129
Bad debt expense	485	107
Gain on sales of real estate	(11,766)	0
Loss on extinguishment of debt, net	4,663	0
Change in fair value of derivative financial instruments	857	(8,573)
Changes in operating assets and liabilities:
Receivables and other assets, net	(4,443)	(13,569)
Accounts payable and accrued liabilities	13,212	21,928
Security deposits, prepaid rent and other liabilities	(2,442)	6,377
Net cash provided by operating activities	129,550	118,675
Cash flows from investing activities:
Acquisition of real estate operating properties	(229,644)	(223,839)
Proceeds from sales of real estate	40,148	0
Capital expenditures	(24,167)	(16,486)
Collection of real estate notes receivable	20,000	0
Issuance of real estate notes receivable	0	(8,520)
Restricted cash, escrow deposits and other assets	(29,318)	(2,446)
Net cash used in investing activities	(222,981)	(251,291)
Cash flows from financing activities:
Proceeds from unsecured senior notes	297,615	297,558
Borrowings on unsecured revolving credit facility	213,000	103,000
Payments on unsecured revolving credit facility	(233,000)	(175,000)
Payments on secured real estate term loan and mortgage loans	(90,389)	(155,302)
Deferred financing costs	(6,093)	(3,471)
Derivative financial instrument termination payments	0	(1,195)
Security deposits	(1,245)	967
Proceeds from issuance of common stock, net	18,016	229,498
Repurchase and cancellation of common stock	(572)	(287)
Dividends	(102,506)	(95,597)
Payment on earnout liability	0	(92)
Distributions to noncontrolling interest of limited partners	(1,061)	(1,238)
Net cash provided by financing activities	93,765	198,841
Net change in cash and cash equivalents	334	66,225
Cash and cash equivalents - beginning of period	18,081	15,956
Cash and cash equivalents - end of period	18,415	82,181
Healthcare Trust of America Holdings, LP (HTALP)
Cash flows from operating activities:
Net income	24,537	20,622
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	101,168	86,654
Share-based compensation expense	3,279	5,129
Bad debt expense	485	107
Gain on sales of real estate	(11,766)	0
Loss on extinguishment of debt, net	4,663	0
Change in fair value of derivative financial instruments	857	(8,573)
Changes in operating assets and liabilities:
Receivables and other assets, net	(4,443)	(13,569)
Accounts payable and accrued liabilities	13,212	21,928
Security deposits, prepaid rent and other liabilities	(2,442)	6,377
Net cash provided by operating activities	129,550	118,675
Cash flows from investing activities:
Acquisition of real estate operating properties	(229,644)	(223,839)
Proceeds from sales of real estate	40,148	0
Capital expenditures	(24,167)	(16,486)
Collection of real estate notes receivable	20,000	0
Issuance of real estate notes receivable	0	(8,520)
Restricted cash, escrow deposits and other assets	(29,318)	(2,446)
Net cash used in investing activities	(222,981)	(251,291)
Cash flows from financing activities:
Proceeds from unsecured senior notes	297,615	297,558
Borrowings on unsecured revolving credit facility	213,000	103,000
Payments on unsecured revolving credit facility	(233,000)	(175,000)
Payments on secured real estate term loan and mortgage loans	(90,389)	(155,302)
Deferred financing costs	(6,093)	(3,471)
Derivative financial instrument termination payments	0	(1,195)
Security deposits	(1,245)	967
Proceeds from issuance of general partner units, net	18,016	229,498
Repurchase and cancellation of general partner units	(572)	(287)
Distributions to general partner	(102,506)	(95,597)
Payment on earnout liability	0	(92)
Distributions to limited partners and redeemable noncontrolling interests	(1,061)	(1,238)
Net cash provided by financing activities	93,765	198,841
Net change in cash and cash equivalents	334	66,225
Cash and cash equivalents - beginning of period	18,081	15,956
Cash and cash equivalents - end of period	$ 18,415	$ 82,181

XML

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Equity:
Preferred stock, par value (usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	200,000,000	200,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class A
Equity:
Common stock, par value (usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	238,944,761	236,880,614
Common stock, shares outstanding	238,944,761	236,880,614
Healthcare Trust of America Holdings, LP (HTALP)
Partners’ Capital:
Limited partner's capital, units issued	2,973,998	3,052,918
Limited partner's capital, units outstanding	2,973,998	3,052,918
General partner's capital, units issued	238,944,761	236,880,614
General partner's capital, units outstanding	238,944,761	236,880,614

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Litigation

We are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material effect on our condensed consolidated financial position, results of operations or cash flows.

Environmental Matters

We follow the policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency.

Other

Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material effect on our condensed consolidated financial position, results of operations or cash flows.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 27, 2014
Entity Information [Line Items]
Entity Registrant Name	HEALTHCARE TRUST OF AMERICA, INC.
Entity Central Index Key	0001360604
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		238,946,821
Healthcare Trust of America Holdings, LP (HTALP)
Entity Information [Line Items]
Entity Registrant Name	Healthcare Trust of America Holdings, LP
Entity Central Index Key	0001495491
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer

XML

Stockholders' Equity and Partners' Capital

9 Months Ended

Sep. 30, 2014

Equity [Abstract]

Stockholders' Equity and Partners' Capital

Stockholders’ Equity and Partners’ Capital

HTALP’s partnership agreement provides that it will distribute cash flows from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner determines. Except for certain LTIP units that have not vested, dividend distributions are made such that a holder of one partnership unit will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of HTA’s common stock. In addition, for each share of common stock issued or redeemed by HTA, HTALP issues or redeems a corresponding number of partnership units.

Common Stock Offerings

On February 28, 2014, HTA amended the at-the-market (“ATM”) offering program of its common stock with an aggregate sales price of up to $300.0 million primarily to add sales agents to the program. During the nine months ended September 30, 2014, HTA issued and sold 1,541,715 shares of common stock, at an average price of $11.86 per share and, as of September 30, 2014, $281.7 million remained available for issuance under the ATM.

Common Stock Dividends

See condensed consolidated statements of operations for the dividends declared during the three and nine months ended September 30, 2014 and 2013. On October 28, 2014, HTA declared a quarterly cash dividend of $0.145 per share to be paid onJanuary 6, 2015 to stockholders of record of its common stock on December 29, 2014.

Incentive Plan

HTA’s Amended and Restated 2006 Incentive Plan (the “Plan”) permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors or the Compensation Committee. The Plan authorizes the granting of awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 10,000,000. As of September 30, 2014, there were 4,594,200 awards available for grant under the Plan.

LTIP Units

Awards under the LTIP consist of Series C units in HTALP, and are subject to the achievement of certain performance and market conditions in order to vest. Once vested, the Series C units are converted into common units of HTALP, which may be converted into shares of HTA’s common stock. For thethree and nine months ended September 30, 2013, we recognized compensation expense related to LTIP awards of$0.0 millionand$3.1 million, respectively, which was recorded in listing expenses. The LTIP awards were fully expensed in 2013, except for approximately$4.5 millionof expense associated with450,000units that will only vest in the event of a change in control. We will not recognize any expense associated with these units until such time as a change in control event occurs or is probable.

The following is a summary of the activity in our LTIP units during 2014:

	LTIP Units		Weighted Average Grant Date Fair Value
Balance as of December 31, 2013	516,500		$	9.43
Granted	—		—
Vested	—		—
Forfeited	(6,020	)	5.62
Balance as of September 30, 2014	510,480		$	9.47

Restricted Common Stock

For the three and nine months ended September 30, 2014, we recognized compensation expense of $1.0 million and $3.3 million, respectively, which was recorded in general and administrative expenses. For the three months ended September 30, 2013, we recognized compensation expense of $0.5 million, which was recorded in general and administrative expenses. For the nine months ended September 30, 2013, we recognized compensation expense of $2.0 million, of which $1.4 million was recorded in general and administrative expenses and $0.6 million was recorded in listing expenses.

As of September 30, 2014, there was approximately $5.2 million of unrecognized compensation expense net of estimated forfeitures, which will be recognized over a remaining weighted average period of 2.0 years.

The following is a summary of the activity in our restricted common stock during 2014:

	Restricted Common Stock		Weighted Average Grant Date Fair Value
Balance as of December 31, 2013	641,000		$	10.34
Granted	563,200		10.21
Vested	(148,000	)	10.07
Forfeited	(55,600	)	9.96
Balance as of September 30, 2014	1,000,600		$	10.46

XML

Condensed Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013
Revenues:
Rental income	$ 95,277		$ 82,349		$ 274,675		$ 235,595
Interest income from real estate notes receivable	257		635		1,834		1,874
Total revenues	95,534		82,984		276,509		237,469
Expenses:
Rental	28,526		25,837		85,179		72,435
General and administrative	5,935		5,980		18,137		18,645
Acquisition-related	2,802		1,403		8,647		3,086
Depreciation and amortization	35,802		29,581		104,346		87,725
Listing	0		0		0		4,405
Total expenses	73,065		62,801		216,309		186,296
Income before other income (expense)	22,469		20,183		60,200		51,173
Interest expense:
Interest related to derivative financial instruments	(1,433)		(1,087)		(4,148)		(3,448)
Net gain (loss) on change in the fair value of derivative financial instruments	2,564		(1,955)		(857)		8,573
Total interest related to derivative financial instruments, including net change in the fair value of derivative financial instruments	1,131		(3,042)		(5,005)		5,125
Interest related to debt	(14,119)		(12,146)		(37,802)		(35,704)
Gain on sales of real estate	11,766		0		11,766		0
Loss on extinguishment of debt, net	(5,028)		0		(4,663)		0
Other income	1		10		41		28
Net income	16,220		5,005		24,537		20,622
Net income attributable to noncontrolling interests	(188)	[1]	(182)	[1]	(358)	[1]	(423)	[1]
Net income attributable to common stockholders/unitholders	16,032		4,823		24,179		20,199
Earnings per common share/unit - basic
Net income attributable to common stockholders/unitholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09
Earnings per common share/unit - diluted:
Net income attributable to common stockholders/unitholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09
Weighted average number of common shares/units outstanding:
Basic (in shares/units)	238,968		232,514		238,099		225,132
Diluted (in shares/units)	241,432		235,023		240,608		226,771
Dividends/Distributions declared per common share/unit (in usd per share/unit)	$ 0.15		$ 0.14		$ 0.43		$ 0.43
Healthcare Trust of America Holdings, LP (HTALP)
Revenues:
Rental income	95,277		82,349		274,675		235,595
Interest income from real estate notes receivable	257		635		1,834		1,874
Total revenues	95,534		82,984		276,509		237,469
Expenses:
Rental	28,526		25,837		85,179		72,435
General and administrative	5,935		5,980		18,137		18,645
Acquisition-related	2,802		1,403		8,647		3,086
Depreciation and amortization	35,802		29,581		104,346		87,725
Listing	0		0		0		4,405
Total expenses	73,065		62,801		216,309		186,296
Income before other income (expense)	22,469		20,183		60,200		51,173
Interest expense:
Interest related to derivative financial instruments	(1,433)		(1,087)		(4,148)		(3,448)
Net gain (loss) on change in the fair value of derivative financial instruments	2,564		(1,955)		(857)		8,573
Total interest related to derivative financial instruments, including net change in the fair value of derivative financial instruments	1,131		(3,042)		(5,005)		5,125
Interest related to debt	(14,119)		(12,146)		(37,802)		(35,704)
Gain on sales of real estate	11,766		0		11,766		0
Loss on extinguishment of debt, net	(5,028)		0		(4,663)		0
Other income	1		10		41		28
Net income	16,220		5,005		24,537		20,622
Net income attributable to noncontrolling interests	(28)	[1]	(9)	[1]	(106)	[1]	(39)	[1]
Net income attributable to common stockholders/unitholders	$ 16,192		$ 4,996		$ 24,431		$ 20,583
Earnings per common share/unit - basic
Net income attributable to common stockholders/unitholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09
Earnings per common share/unit - diluted:
Net income attributable to common stockholders/unitholders (usd per share)	$ 0.07		$ 0.02		$ 0.10		$ 0.09
Weighted average number of common shares/units outstanding:
Basic (in shares/units)	241,948		235,570		241,124		228,188
Diluted (in shares/units)	241,948		235,570		241,124		228,188
Dividends/Distributions declared per common share/unit (in usd per share/unit)	$ 0.15		$ 0.14		$ 0.43		$ 0.43

[1] Includes amounts attributable to redeemable noncontrolling interests.

XML

Real Estate Notes Receivable

9 Months Ended

Sep. 30, 2014

Receivables [Abstract]

Real Estate Notes Receivable

Real Estate Notes Receivable

As of December 31, 2013, we had $28.5 million in real estate notes receivable secured by medical office buildings. During the nine months ended September 30, 2014, $20.0 million of our real estate notes receivable were repaid by the borrower. As of September 30, 2014, we had two promissory notes outstanding totaling an aggregate amount of $8.5 million. Each of the promissory notes has an interest rate of 7.0% per annum and mature on October 1, 2016. We are advised by the property owner/borrower that the properties are being actively marketed for sale and the outstanding notes will be repaid upon sale.

We monitor the credit quality of our real estate notes receivable on an ongoing basis by tracking possible credit quality indicators. As of September 30, 2014, our real estate notes receivable are current and we have not provided for any allowance for losses or recorded any impairments. We made no purchases or sales of real estate notes receivable during the nine months ended September 30, 2014.

XML

Dispositions and Assets Held for Sale

9 Months Ended

Sep. 30, 2014

Property, Plant and Equipment [Abstract]

Dispositions and Assets Held for Sale

Dispositions and Assets Held for Sale

During the three months ended September 30, 2014, we had two dispositions of portfolios of medical office buildings for an aggregate gross sales price of $42.0 million resulting in a gain of $11.8 million.  In addition, we entered into a purchase and sale agreement as the seller and received a non-refundable deposit from the purchaser for the sale of an additional portfolio of medical office buildings for gross proceeds of $40.9 million.  This portfolio, which includes $18.9 million of real estate investments and $3.1 million of other intangibles, was reclassified to assets held for sale during the third quarter of 2014.  Our sale of these medical office buildings closed in October 2014 resulting in a gain of approximately $16 million. 

During 2013, we had one property within our portfolio that met the criteria for classification as held for sale. Accordingly, we presented the assets and liabilities separately and included the results of operations within discontinued operations for all periods presented. Additionally, we ceased recording depreciation and amortization following the held for sale designation. During the quarter ended March 31, 2014, we determined that it was appropriate to reclassify the property out of held for sale in our condensed consolidated balance sheets and to include the results of operations within the results of operations of our operating properties in our condensed consolidated statements of operations for all periods presented as the property no longer met the criteria for classification as held for sale. We measured the property to be reclassified at the lower of its carrying value before it was classified as held for sale (adjusted for any depreciation and amortization expense that would have been recognized had the property been continuously classified as held and used) or its fair value at the date of the subsequent decision not to sell. As such, during the quarter ended March 31, 2014, we recorded $0.8 million of depreciation and amortization expense which represents the depreciation and amortization on the property that was not recorded when it was classified as held for sale.

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

Interim Unaudited Financial Data

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2013 Annual Report on Form 10-K.

Variable Interest Entities

Variable Interest Entities

As of September 30, 2014, our condensed consolidated financial statements include four VIEs, which we were deemed to be the primary beneficiary. All of the VIEs were established during the third quarter of 2014 to facilitate potential Section 1031 Exchanges.

Noncontrolling Interests

Noncontrolling Interests

HTA’s net income attributable to noncontrolling interests in the accompanying condensed consolidated statements of operations relate to both noncontrolling interest reflected within equity and redeemable noncontrolling interest of limited partners reflected outside of equity in the accompanying condensed consolidated balance sheets. Limited partner units, including LTIP awards, are accounted for as partners’ capital in HTALP’s accompanying condensed consolidated balance sheets and as noncontrolling interest reflected within equity or redeemable noncontrolling interest of limited partners reflected outside of equity in HTA’s accompanying condensed consolidated balance sheets.

Redeemable noncontrolling interests relate to the interests in our consolidated entities that are not wholly owned by us. As these redeemable noncontrolling interests provide for redemption features not solely within our control, we classify such interests outside of permanent equity or partners’ capital.

Recently Issued or Adopted Accounting Pronouncements

Recently Issued or Adopted Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Updated (“ASU”) 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360) which changes the requirements for reporting discontinued operations. ASU 2014-08 changes the threshold for disclosing discontinued operations and the related disclosure requirements. Pursuant to ASU 2014-08, only disposals representing a strategic shift, such as a major line of business, a major geographical area or majority equity investment, should be presented as a discontinued operation. If the disposal does qualify as a discontinued operation under ASU 2014-08, the entity will be required to provide expanded disclosures. The guidance will be applied prospectively to new disposals and new classifications of disposal groups held for sale after the effective date. ASU 2014-08 is effective for annual periods beginning on or after December 15, 2014 with early adoption permitted but only for disposals or classifications as held for sale which have not been reported in financial statements previously issued or available for issuance. We adopted ASU 2014-08 as of January 1, 2014 and believe future sales of our individual operating properties will no longer qualify as discontinued operations.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. ASU 2014-09 is effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. We are still evaluating the impact of adopting ASU 2014-09 on our financial statements.

In June 2014, the FASB issued ASU 2014-12, Compensation - Stock Compensation (Topic 718). ASU 2014-12 requires that a performance target requisite service period be treated as a performance condition and, as a result, this type of performance condition may delay expense recognition until achievement of the performance target is probable. ASU 2014-12 is effective for reporting periods beginning after December 15, 2015, and early adoption is permitted. We will adopt ASU 2014-12 effective January 1, 2016 and it is not anticipated to have a material impact on our financial statements.

XML

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Financial Instruments Reported at Fair Value

The table below presents our assets and liabilities measured at fair value on a recurring basis as of September 30, 2014, aggregated by the applicable Level in the fair value hierarchy (in thousands):

	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1 )		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Derivative financial instruments	$	—	$	3,290	$	—	$	3,290
Liabilities:
Derivative financial instruments	$	—	$	4,127	$	—	$	4,127

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2013, aggregated by the applicable Level in the fair value hierarchy (in thousands):

	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1 )		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Derivative financial instruments	$	—	$	5,073	$	—	$	5,073
Liabilities:
Derivative financial instruments	$	—	$	5,053	$	—	$	5,053

There have been no transfers of assets or liabilities between Levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our interest rate swap derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our interest rate swap derivative positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our interest rate swap derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Financial Instruments Disclosed at Fair Value

We consider the carrying values of cash and cash equivalents, accounts and other receivables, restricted cash and escrow deposits, and accounts payable and accrued liabilities to approximate fair value for these financial instruments because of the short period of time between origination of the instruments and their expected realization. All of these financial instruments are considered Level 2. The fair value of the real estate notes receivable and tenant note receivable are estimated by discounting the expected cash flow on the notes at current rates for loans with similar maturities. The fair value of debt is estimated using borrowing rates available to us with similar terms and maturities. The following table sets forth the carrying value and fair value of our real estate notes receivable, tenant note receivable and debt (in thousands):

		September 30, 2014				December 31, 2013
	Fair Value Level	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Real estate notes receivable	2	$	8,520	$	8,520	$	28,520	$	28,520
Tenant note receivable	2	3,080		3,028		3,173		3,013
Debt	2	1,497,136		1,509,761		1,214,241		1,237,699

XML

Debt

9 Months Ended

Sep. 30, 2014

Debt Disclosure [Abstract]

Debt

Debt

Debt consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014			December 31, 2013
Unsecured revolving credit facility	$	35,000		$	55,000
Unsecured term loans	455,000			455,000
Unsecured senior notes	600,000			300,000
Fixed rate mortgages	379,196			373,751
Variable rate mortgages	29,590			29,925
	1,498,786			1,213,676
Net premium (discount)	(1,650		)	565
Total	$	1,497,136		$	1,214,241

Unsecured Credit Agreement

Unsecured Revolving Credit Facility

HTA’s and HTALP’s $650.0 million unsecured revolving credit facility matures on March 29, 2016 and includes a one-year extension, at the option of the borrower, subject to certain conditions. The actual amount of credit available to us is a function of certain loan-to-value and debt service coverage ratios set forth in the credit facility. The maximum principal amount of the credit facility may be increased, subject to additional financing being provided by our existing lenders or new lenders being added to the unsecured revolving credit facility.

Borrowings under the $650.0 million unsecured revolving credit facility accrue interest equal to adjusted LIBOR, plus a margin ranging from 1.10% to 1.75% per annum based on our credit rating. We also pay a facility fee ranging from 0.20% to 0.50% per annum on the aggregate commitments under the unsecured revolving credit facility. As of September 30, 2014, the margin associated with our borrowings was 1.30% per annum and the facility fee was 0.25% per annum.

Unsecured Term Loan

On January 7, 2014, HTA and HTALP executed an amendment to the unsecured credit agreement that decreased the interest rate on the unsecured term loan and extended the maturity date. Borrowings under the $300.0 million unsecured term loan accrue interest equal to adjusted LIBOR, plus a margin ranging from 1.05% to 1.95% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2014 was 1.20% per annum. We have interest rate swaps in place that fix the interest rate at 2.30% per annum, based on our current credit rating. The unsecured term loan matures on January 31, 2018 and includes a one-year extension, at the option of the borrower, subject to certain conditions.

$155.0 Million Unsecured Term Loan

On July 20, 2012, HTALP entered into a $155.0 million unsecured term loan that is guaranteed by HTA. The loan matures on July 19, 2019 and the interest rate thereon is equal to LIBOR, plus a margin ranging from 1.55% to 2.40% per annum based on our credit rating. The margin associated with our borrowings as of September 30, 2014 was 1.70% per annum. We have interest rate swaps in place that fix the interest rate at 2.99% per annum, based on our current credit rating. The maximum principal amount under this unsecured term loan may be increased by us, subject to such additional financing being provided by our existing lender.

$300.0 Million Unsecured Senior Notes due 2023

On March 28, 2013, HTALP issued $300.0 million of unsecured senior notes guaranteed by HTA that mature on April 15, 2023. The unsecured senior notes are registered under the Securities Act of 1933, as amended (the “Securities Act”), bear interest at 3.70% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.186% of the principal amount thereof, with an effective yield to maturity of 3.80% per annum.

$300.0 Million Unsecured Senior Notes due 2021

On June 26, 2014, HTALP issued $300.0 million of unsecured senior notes guaranteed by HTA that mature on July 15, 2021. The unsecured senior notes are registered under the Securities Act, bear interest at 3.375% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.205% of the principal amount thereof, with an effective yield to maturity of 3.50% per annum.

Fixed and Variable Rate Mortgages

As of September 30, 2014, HTALP and its subsidiaries had fixed and variable rate mortgages with interest rates ranging from 1.60% to 12.75% per annum and a weighted average interest rate of 5.31% per annum. Including the impact of the interest rate swap associated with our variable rate mortgage, the weighted average interest rate was 5.56% per annum. During 2014, we assumed certain fixed rate mortgage loans, see Note 3.

Future Debt Maturities

The following table summarizes the debt maturities and scheduled principal repayments as of September 30, 2014 (in thousands):

Year	Amount
2014	$	2,105
2015	73,454
2016	104,625
2017	102,744
2018	314,881
Thereafter	900,977
Total	$	1,498,786

The above scheduled debt maturities do not include the extensions available to us under the unsecured credit agreement as discussed above.

We are required by the terms of our applicable debt agreements to meet various affirmative and negative covenants that we believe are customary for these types of facilities, such as limitations on the incurrence of debt by us, and our subsidiaries that own unencumbered assets, limitations on the nature of HTALP’s business, and limitations on distributions by HTALP and its subsidiaries that own unencumbered assets. Our debt agreements also impose various financial covenants on us, such as a maximum ratio of total indebtedness to total asset value, a minimum ratio of EBITDA to fixed charges, a minimum tangible net worth covenant, a maximum ratio of unsecured indebtedness to unencumbered asset value, rent coverage ratios, and a minimum ratio of unencumbered net operating income to unsecured interest expense. As of September 30, 2014, we believe that we were in compliance with all such financial covenants and reporting requirements. In addition, certain of our debt agreements include events of default provisions that we believe are customary for these types of facilities, including restricting HTA from making dividend distributions to its stockholders in the event HTA is in default thereunder, except to the extent necessary for HTA to maintain its REIT status.

XML

Intangibles Assets and Liabilities

9 Months Ended

Sep. 30, 2014

Identified Intangibles, Net [Abstract]

Intangibles Assets and Liabilities

Intangible Assets and Liabilities

Intangible assets and liabilities consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands, except weighted average remaining amortization period):

	September 30, 2014				December 31, 2013
	Balance			Weighted Average Remaining Amortization Period in Years	Balance			Weighted Average Remaining Amortization Period in Years	Balance Sheet Classification
Assets:
In place leases	$	225,023		8.6	$	213,338		8.8	Lease intangibles
Tenant relationships	188,380			10.4	198,519			10.5	Lease intangibles
Above market leases	26,566			5.8	26,799			6.3	Other intangibles, net
Below market leasehold interests	31,393			67.7	37,640			68.9	Other intangibles, net
	471,362				476,296
Accumulated amortization	(172,708		)		(151,860		)
Total	$	298,654		15.4	$	324,436		15.9
Liabilities:
Below market leases	$	13,999		12.1	$	13,989		12.4	Intangible liabilities, net
Above market leasehold interests	3,827			32.4	3,827			33.1	Intangible liabilities, net
	17,826				17,816
Accumulated amortization	(6,306		)		(6,019		)
Total	$	11,520		18.1	$	11,797		18.4

The following is a summary of the net intangible amortization for the three and nine months ended September 30, 2014 and 2013 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Amortization recorded against rental income related to above or below market leases	$	505	$	417	$	1,534	$	1,298
Rental expense related to above or below market leasehold interests	112		89		358		278
Amortization expense related to in place leases and tenant relationships	12,066		9,955		36,247		29,970

XML

Receivables and Other Assets

9 Months Ended

Sep. 30, 2014

Receivables and Other Assets [Abstract]

Receivables and Other Assets

Receivables and Other Assets

Receivables and other assets consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014		December 31, 2013
Accounts and other receivables, net	$	23,749	$	22,847
Tenant note receivable	3,080		3,173
Deferred financing costs, net	12,418		10,921
Deferred leasing costs, net	16,616		13,500
Lease inducements, net	807		771
Straight-line rent receivables, net	54,057		47,317
Prepaid expenses, deposits, equipment and other, net	27,544		6,683
Derivative financial instruments - interest rate swaps	3,290		5,073
Total	$	141,561	$	110,285

The following is a summary of amortization of deferred leasing costs, deferred financing costs, and lease inducements for the three and nine months ended September 30, 2014 and 2013 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Amortization expense related to deferred leasing costs	$	957	$	686	$	2,646	$	1,862
Interest expense related to deferred financing costs	724		805		2,319		3,084
Amortization recorded against rental income related to lease inducements	50		56		168		173

XML

Derivative Financial Instruments

9 Months Ended

Sep. 30, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

Derivative Financial Instruments

The following table lists the derivative financial instrument assets and (liabilities) held by us as of September 30, 2014 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	200,000	LIBOR	1.23	%	$	(1,404	)	Swap	3/29/2017
100,000		LIBOR	0.86		(465		)	Swap	6/15/2016
50,000		LIBOR	1.39		812			Swap	7/17/2019
105,000		LIBOR	1.24		2,478			Swap	7/17/2019
27,062		LIBOR	4.98		(2,258		)	Swap	5/1/2020

The following table lists the derivative financial instrument assets and (liabilities) held by us as of December 31, 2013 (in thousands):

Notional Amount		Index	Rate		Fair Value			Instrument	Maturity
$	200,000	LIBOR	1.23	%	$	(2,078	)	Swap	3/29/2017
100,000		LIBOR	0.86		(729		)	Swap	6/15/2016
50,000		LIBOR	1.39		1,350			Swap	7/17/2019
105,000		LIBOR	1.24		3,723			Swap	7/17/2019
27,618		LIBOR	4.98		(2,246		)	Swap	5/1/2020

As of September 30, 2014 and December 31, 2013, the gross fair value of our derivative financial instruments was as follows (in thousands):

	Asset Derivatives					Liability Derivatives
		Fair Value					Fair Value
Derivatives Not Designated as Hedging Instruments:	Balance Sheet Location	September 30, 2014		December 31, 2013		Balance Sheet Location	September 30, 2014		December 31, 2013
Interest rate swaps	Receivables and other assets	$	3,290	$	5,073	Derivative financial instruments	$	4,127	$	5,053

There were no derivatives offset in our accompanying condensed consolidated balance sheets as of September 30, 2014 and December 31, 2013. As of September 30, 2014 and December 31, 2013, we had derivatives subject to enforceable master netting arrangements which allowed for net cash settlement with the respective counterparties (in thousands):

	September 30, 2014							December 31, 2013
	Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts		Gross Amounts		Amounts Subject to Enforceable Master Netting Arrangements			Net Amounts
Asset derivatives	$	3,290	$	(1,404	)	$	1,886	$	5,073	$	(2,078	)	$	2,995
Liability derivatives	4,127		(1,404		)	2,723		5,053		(2,078		)	2,975

We have agreements with each of our interest rate swap derivative counterparties that contain a provision whereby if we default on certain of our unsecured indebtedness, then our counterparties could declare us in default on our interest rate swap derivative obligations resulting in an acceleration of the indebtedness. In addition, we are exposed to credit risk in the event of non-performance by our derivative counterparties. We believe we mitigate the credit risk by entering into agreements with credit-worthy counterparties. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, our fair value of interest rate swap derivative liabilities is adjusted to reflect the impact of our credit quality. As of September 30, 2014, there have been no termination events or events of default related to our interest rate swaps.

XML

Organization and Description of Business (Details) (USD $) In Billions, unless otherwise specified	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General partnership interest percentage	99.00%
Purchased property inception to current date	$ 3.3

XML

Fair Value of Financial Instruments (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Real estate notes receivable	$ 8,520	$ 28,520
Tenant note receivable	3,080	3,173
Debt	1,497,136	1,214,241
Fair Value Level 2 | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Real estate notes receivable	8,520	28,520
Tenant note receivable	3,080	3,173
Debt	1,497,136	1,214,241
Fair Value Level 2 | Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Real estate notes receivable	8,520	28,520
Tenant note receivable	3,028	3,013
Debt	$ 1,509,761	$ 1,237,699

XML

Per Unit Data of HTALP

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Per Unit Data of HTALP

Per Unit Data of HTALP

The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and nine months ended September 30, 2014 and 2013 (in thousands, except per unit data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Numerator:
Net income	$	16,220		$	5,005		$	24,537		$	20,622
Net income attributable to noncontrolling interests	(28		)	(9		)	(106		)	(39		)
Net income attributable to common unitholders	$	16,192		$	4,996		$	24,431		$	20,583
Denominator:
Weighted average number of units outstanding - basic	241,948			235,570			241,124			228,188
Dilutive units	—			—			—			—
Weighted average number of units outstanding - diluted	241,948			235,570			241,124			228,188
Earnings per common unit - basic:
Net income attributable to common unitholders	$	0.07		$	0.02		$	0.10		$	0.09
Earnings per common unit - diluted:
Net income attributable to common unitholders	$	0.07		$	0.02		$	0.10		$	0.09

XML

Receivables and Other Assets (Tables)

9 Months Ended

Sep. 30, 2014

Receivables and Other Assets [Abstract]

Schedule of Receivables and Other Assets

Receivables and other assets consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014		December 31, 2013
Accounts and other receivables, net	$	23,749	$	22,847
Tenant note receivable	3,080		3,173
Deferred financing costs, net	12,418		10,921
Deferred leasing costs, net	16,616		13,500
Lease inducements, net	807		771
Straight-line rent receivables, net	54,057		47,317
Prepaid expenses, deposits, equipment and other, net	27,544		6,683
Derivative financial instruments - interest rate swaps	3,290		5,073
Total	$	141,561	$	110,285

Schedule of Receivables and Other Assets Amortization Expense

The following is a summary of amortization of deferred leasing costs, deferred financing costs, and lease inducements for the three and nine months ended September 30, 2014 and 2013 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Amortization expense related to deferred leasing costs	$	957	$	686	$	2,646	$	1,862
Interest expense related to deferred financing costs	724		805		2,319		3,084
Amortization recorded against rental income related to lease inducements	50		56		168		173

XML

Stockholders' Equity and Partners' Capital - Nonvested Rollforward (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
LTIP
Stocks/Units:
Balance as of beginning of period (in shares)	516,500
Granted (in shares)	0
Vested (in shares)	0
Forfeited (in shares)	(6,020)
Balance as of end of period (in shares)	510,480
Weighted Average Grant Date Fair Value:
Balance as of beginning of period (in usd per share)	$ 9.43
Granted (in usd per share)	$ 0.00
Vested (in usd per share)	$ 0.00
Forfeited (in usd per share)	$ 5.62
Balance as of end of period (in usd per share)	$ 9.47
Restricted Stock
Stocks/Units:
Balance as of beginning of period (in shares)	641,000
Granted (in shares)	563,200
Vested (in shares)	(148,000)
Forfeited (in shares)	(55,600)
Balance as of end of period (in shares)	1,000,600
Weighted Average Grant Date Fair Value:
Balance as of beginning of period (in usd per share)	$ 10.34
Granted (in usd per share)	$ 10.21
Vested (in usd per share)	$ 10.07
Forfeited (in usd per share)	$ 9.96
Balance as of end of period (in usd per share)	$ 10.46

XML

Receivables and Other Assets (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Receivables and Other Assets [Abstract]
Accounts and other receivables, net	$ 23,749		$ 23,749		$ 22,847
Tenant note receivable	3,080		3,080		3,173
Deferred financing costs, net	12,418		12,418		10,921
Deferred leasing costs, net	16,616		16,616		13,500
Lease inducements, net	807		807		771
Straight-line rent receivables, net	54,057		54,057		47,317
Prepaid expenses, deposits, equipment and other, net	27,544		27,544		6,683
Derivative financial instruments - interest rate swaps	3,290		3,290		5,073
Total	141,561		141,561		110,285
Amortization expense related to deferred leasing costs	957	686	2,646	1,862
Interest expense related to deferred financing costs	724	805	2,319	3,084
Amortization recorded against rental income related to lease inducements	$ 50	$ 56	$ 168	$ 173

XML

Condensed Consolidated Statements of Equity (USD $) In Thousands, except Share data, unless otherwise specified	Total USD ($)	Class A	Common Stock USD ($)	Common Stock Class A	Common Stock Class B	Additional Paid-In Capital USD ($)	Cumulative Dividends in Excess of Earnings USD ($)	Total Stockholders’ Equity USD ($)	Noncontrolling Interest USD ($)
Beginning balance at Dec. 31, 2012	$ 1,264,595		$ 2,147			$ 1,885,836	$ (633,717)	$ 1,254,266	$ 10,329
Beginning balance, shares at Dec. 31, 2012				100,086,000	114,566,000
Increase (Decrease) in Stockholders' Equity
Issuance of common stock (in shares)				20,707,000
Issuance of common stock	228,306		207			228,099		228,306
Share-based award transactions, net (in shares)				427,000	(15,000)
Share-based award transactions, net	5,129		4			1,948		1,952	3,177
Repurchase and cancellation of common stock (in shares)				(28,000)
Repurchase and cancellation of common stock	(287)		0			(287)		(287)
Conversion				57,283,000	(57,283,000)
Dividends	(99,584)						(98,630)	(98,630)	(954)
Net income	20,552						20,199	20,199	353
Ending balance at Sep. 30, 2013	1,418,711		2,358			2,115,596	(712,148)	1,405,806	12,905
Ending balance, shares at Sep. 30, 2013				178,475,000	57,268,000
Beginning balance at Dec. 31, 2013	1,399,749		2,369			2,126,897	(742,060)	1,387,206	12,543
Beginning balance, shares at Dec. 31, 2013		236,880,614		236,880,000
Increase (Decrease) in Stockholders' Equity
Issuance of common stock (in shares)				1,542,000
Issuance of common stock	17,742		16			17,726		17,742
Share-based award transactions, net (in shares)				508,000
Share-based award transactions, net	3,279		5			3,274		3,279	0
Repurchase and cancellation of common stock (in shares)				(58,000)
Repurchase and cancellation of common stock	(572)		(1)			(571)		(572)
Redemption of noncontrolling interest (in shares)				73,000
Redemption of noncontrolling interest						362		362	(362)
Dividends	(103,951)						(103,097)	(103,097)	(854)
Net income	24,415						24,179	24,179	236
Ending balance at Sep. 30, 2014	$ 1,340,662		$ 2,389			$ 2,147,688	$ (820,978)	$ 1,329,099	$ 11,563
Ending balance, shares at Sep. 30, 2014		238,944,761		238,945,000	0

XML

Business Combinations

9 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Business Combinations

Business Combinations

For the nine months ended September 30, 2014, we had five acquisitions for an aggregate purchase price of $317.6 million. We incurred $5.6 million of costs attributable to these acquisitions. As part of the acquisitions, we assumed mortgage loans with an aggregate fair value of$91.5 million.

Since the acquisitions were determined to be individually not significant, but material on a collective basis, the allocations for the 2014 acquisitions are set forth below in the aggregate (in thousands):

2014 Acquisitions	Total
Land	$	70,609
Building and improvements	227,458
Below market leasehold interests	98
Above market leases	1,708
In place leases	22,233
Below market leases	(953		)
Above market debt, net	(2,664		)
Net assets acquired	318,489
Other, net	(939		)
Aggregate purchase price	$	317,550

The weighted average lives of the above acquired intangible assets and liabilities were 9.1 years and 8.5 years, respectively.

The following is a brief description of each of the acquisitions.

• In June 2014, we acquired a portfolio of medical office buildings located in Boston, Massachusetts; Miami, Florida; and Baltimore, Maryland, for an aggregate purchase price of $200.0 million.

• In June 2014, we acquired a medical office building located in Raleigh, North Carolina for $11.5 million.

• In August 2014, we acquired a portfolio of medical office buildings located in White Plains, New York for $64.0 million.

• In August 2014, we acquired a medical office building located in Charleston, South Carolina for $24.8 million.

• In September 2014, we acquired a medical office building located in Clearwater, Florida for $17.3 million.

The acquisitions completed during the nine months ended September 30, 2013 were determined to be individually not significant, but material on a collective basis. The allocations for these acquisitions are set forth below in the aggregate (in thousands):

2013 Acquisitions	Total
Land	$	13,415
Building and improvements	175,039
Below market leasehold interests	1,836
Above market leases	1,987
In place leases	32,205
Tenant relationships	16,541
Below market leases	(1,167		)
Above market debt	(241		)
Net assets acquired	239,615
Other, net	2,299
Aggregate purchase price	$	241,914

The weighted average lives of the above acquired intangible assets and liabilities were 7.4 years and 5.7 years, respectively.

XML

Debt (Tables)

9 Months Ended

Sep. 30, 2014

Debt Disclosure [Abstract]

Schedule of Debt

Debt consisted of the following as of September 30, 2014 and December 31, 2013 (in thousands):

	September 30, 2014			December 31, 2013
Unsecured revolving credit facility	$	35,000		$	55,000
Unsecured term loans	455,000			455,000
Unsecured senior notes	600,000			300,000
Fixed rate mortgages	379,196			373,751
Variable rate mortgages	29,590			29,925
	1,498,786			1,213,676
Net premium (discount)	(1,650		)	565
Total	$	1,497,136		$	1,214,241

Schedule of Maturities of Long-term Debt

The following table summarizes the debt maturities and scheduled principal repayments as of September 30, 2014 (in thousands):

Year	Amount
2014	$	2,105
2015	73,454
2016	104,625
2017	102,744
2018	314,881
Thereafter	900,977
Total	$	1,498,786

XML

Real Estate Notes Receivable (Details) (USD $)	9 Months Ended
	Sep. 30, 2014 promissory_notes	Sep. 30, 2013	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total real estate notes receivable	$ 8,500,000		$ 28,500,000
Collection of real estate notes receivable	$ 20,000,000	$ 0
Number of promissory notes secured by office buildings	2
Portfolio One
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate	7.00%
Portfolio Two
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate	7.00%

XML

Per Share Data of HTA

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Per Share Data of HTA

Per Share Data of HTA

HTA includes unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents as “participating securities” pursuant to the two-class method. The resulting classes are our common stock and restricted stock. For the three and nine months ended September 30, 2014 and 2013, all of HTA’s earnings were distributed and the calculated earnings per share amount would be the same for all classes. The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA common stock for the three and nine months ended September 30, 2014 and 2013 (in thousands, except per share data):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Numerator:
Net income	$	16,220		$	5,005		$	24,537		$	20,622
Net income attributable to noncontrolling interests	(188		)	(182		)	(358		)	(423		)
Net income attributable to common stockholders	$	16,032		$	4,823		$	24,179		$	20,199
Denominator:
Weighted average number of shares outstanding - basic	238,968			232,514			238,099			225,132
Dilutive shares	2,464			2,509			2,509			1,639
Weighted average number of shares outstanding - diluted	241,432			235,023			240,608			226,771
Earnings per common share - basic
Net income attributable to common stockholders	$	0.07		$	0.02		$	0.10		$	0.09
Earnings per common share - diluted
Net income attributable to common stockholders	$	0.07		$	0.02		$	0.10		$	0.09